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SUMMARY 
 
Although Artemisia afra, Leonotis leonorus and Mentha longifolia have been shown to 
possess respiratory smooth muscle relaxant properties, little is known about the 
mechanisms for this effect. These plants contain flavonoids, which are reported to have 
phosphodiesterase (PDE), particularly PDE 4, inhibitory activity that can contribute to 
the plant actions. The smooth muscle relaxant activity of Artemisia afra, L. leonorus and 
M. longifolia may thus, be mediated via inhibition of cyclic adenosine monophosphate 
(cAMP) phosphodiesterase by, among others, the flavonoids. 
 
The specific objectives of this study were to investigate whether Artemisia afra, 
Leonotis leonorus and Mentha longifolia have PDE 4 inhibitory activity, to determine 
and compare the levels of the total phenolic compounds, total and individual flavonoids, 
especially luteolin and hesperetin, in the three plants and, finally, to determine if there 
was a correlation between the PDE inhibitory activity and the levels of flavonoids or 
phenolic compounds in the plants. It was hypothesized that the plants with higher levels 
of total flavonoid and/or aglycone luteolin and/or hesperetin had higher PDE 4 
inhibitory activity. 
 
To realize the above objectives, freeze-dried aqueous extracts of the three plants were 
prepared, the PDE inhibitory activity of desalinated aqueous solutions of the extracts 
determined using the Biomol Green TM Phosphodiesterase Assay and the total flavonoid 
content (TFC), total phenolic compound content (TPC) and individual flavonoid marker 
levels of the extracts determined by the aluminium chloride, Folin Ciocalteu and an 
HPLC assay methods, respectively. 
 
The desalinated aqueous solutions of all three species dose dependently inhibited PDE 4. 
The IC50 for PDE-4 inhibition were 161.7 ± 0.01, 212.1 ± 0.04 and 337.1 ± 0.04 µg/ml 
for the desalinated unhydrolyzed extracts of A. afra, L. leonorus and M. longifolia, 
respectively, and 144 ± 0.358, 167.3 ± 0.037 and 280.2 ± 0.0329 µg/ml, respectively for 
the hydrolyzed extracts. Thus, the PDE 4 inhibitory potency order was A. afra > L. 
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leonorus > M. longifolia. Before desalination with Amberlite MB-1 ion exchanger resin, 
the unhydrolyzed A. afra extracts contained the highest levels of TFC (84.70 ± 
3.88µg/mg), followed by L. leonorus (40.89 ± 0.02 µg/mg) and finally M. longifolia 
(30.4 ±1.08 µg/mg). After acid hydrolysis, the TFC for L leonorus & M. longifolia were 
significantly increased (92.60 ± 9.94 and 94.12 ± 3.94µg/mg, respectively) compared to 
the levels in the unhydrolyzed extracts. The highest TPC was registered in M. longifolia 
(672.66 ± 0 µg/mg) followed by A. afra (357.18 ± 8.99 µg/mg) and finally L leonorus 
(347.36 ± 3.04 µg/mg). On the other hand, acid-hydrolysis significantly increased the 
levels of TPC in all three plant extracts (489.36 ± 6.21, 371.72 ±11.5, and 833.41 ± 9.29 
µg/mg) and treatment the Amberlite MB-1 decreased the plant extracts TPC. The 
unhydrolyzed and hydrolyzed aqueous extracts of A. afra and L. leonorus contained 0.85 
± 0.42 µg/mg, 0.92 ± 0.105 µg/mg and 0.427 ± 0.032 µg/mg, 0.559 ± 0.075 µg/mg, 
respectively. M. longifolia aqueous extract contained 0.147µg/mg of hesperetin which 
was not detected in the hydrolyzed extracts. Desalination treatment with Amberlite MB-1 
resin caused a decrease in the levels of luteolin in A. afra and L. leonorus and hesperetin 
in M. longifolia extracts. There was no correlation between the TFC and the PDE 4 IC50 
of the plant extracts (r = - 0.18, p value = 0.46), but a significant correlation between the 
TPC, the individual flavonoid markers, luteolin and hesperetin, levels and the plants PDE 
4 IC50 ( r = 0.82, p value < 0.0001, - 0.724, p value = 0.023, respectively) suggesting that 
flavonoids and phenolic compounds may possibly contribute to the plant activity. 
 
In summary, the desalinated aqueous solutions of A. afra, L. leonorus and M. longifolia 
have PDE 4 inhibitory activity and, flavonoids and phenolic compounds are likely to be 
involved in this activity of the plants.  
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CHAPTER 1 
INTRODUCTION 
 
African people have been using medicinal plants for thousands of years and it is 
estimated that 80% of South African population still use them for their health care. 
Despite their popularity and use over many centuries, only a few plants have been 
scientifically validated in South Africa (Springfield et al., 2005). There is, therefore, a 
need for data related to the quality, safety and efficacy of South African medicinal plants. 
In addition, the knowledge of these plants may allow the discovery of new alternatives 
for the treatment of many diseases. In fact, with the view to guarantee an acceptable and 
affordable health care to all countries, the World Health Organization (WHO) has 
encouraged the rational use of traditional medicines (Springfield et al., 2005). Since the 
world is technically well equipped today and has a better understanding of the physiology 
of the human body, it is easier and more convenient to elucidate the scientific rationale 
that may underpin the effectiveness of some of these plant medicines. 
  
Artemisia afra, Leonotis leonorus and Mentha longifolia are among the most popular 
medicinal plants used in South African traditional medicine (Thring and Weitz, 2006). 
These plant species are traditionally used for the treatment of multiple and diverse 
ailments. However, they do have many common features such as some of their uses, 
claimed activities and constituents. For instance, all three species are traditionally used 
for asthma, and have been shown to possess respiratory smooth muscle relaxant 
properties. However, little is known about the mechanisms through which they produce 
this effect and the plant chemical constituents possibly involved. These three plant 
species contain flavonoids that are naturally occurring polyphenolic compounds and have 
a wide distribution in the plant kingdom (Ko et al., 2005). One of the flavones common 
to these plant species, viz. luteolin has been shown to possess tracheal muscle relaxant 
effect that may be mediated via inhibition of cAMP-phosphodiesterase (PDE) (Ko et al., 
2005. Since these plants contain flavonoids, which are reported to inhibit the activity of 
phosphodiesterases, PDE inhibition could be one of the mechanisms by which they 
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produce their anti-asthmatic properties. However, this mechanism has not yet been 
investigated for these three species.  
 
The major objective of this study was, therefore, to investigate whether Artemisia afra, 
Leonotis leonorus and Mentha longifolia have PDE inhibitory activity, and specifically 
the ability to inhibit PDE 4, which is predominant in asthma. The second objective was to 
determine the levels of the phenolic compounds, the total flavonoids and particularly 
luteolin or hesperetin that may have PDE 4 inhibitory activity and contribute to the plant 
activity. The final objective was to compare the PDE inhibitory activity of these three 
plant species and correlate it to the levels of phenolic compounds and flavonoids in the 
plants.  
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CHAPTER 2 
LITERATURE REVIEW 
 
In this chapter a brief description of the selected plant species Artemisia afra, Leonotis 
leonorus and Mentha longifolia is given as well as the chemistry, classification, 
biological activity and the analytical techniques suitable for the determination of 
flavonoids and total phenolic compound levels in plant materials are discussed. In 
addition, the definition and the current treatment of asthma and an overview of the 
molecular mechanism of action of cyclic nucleotides, the classification and structural 
biology of phosphodiesterases and the method to determine the phosphodiesterase 
inhibitory activity of compounds are presented.    
 
2.1. Artemisia afra, Leonotis leonorus and Mentha longifolia 
2.1.1. Artemisia  afra Jacq. 
 
Artemisia afra (A. afra) belongs to the family Asteraceae and is known as African 
wormwood in English; als, alsem or wilde als in Afrikaans; umlhonyane in Xhosa and 
Zulu and lengana in Sotho and Tswana (Van Wyk et al., 2000). 
 
Artemisia afra is a very common species and easily recognised medicinal plant in 
Southern Africa. It is an erect multi-stemmed perennial shrub of up to two meters in 
height. It has feathery leaves that are finely divided and usually have a greyish-green 
colour. Flowers that are pale yellowish are borne along the branch ends (Van Wyk et al., 
2000). The plant’s natural distribution stretches from the southern regions of Africa 
northwards into tropical east Africa, as far north as Ethiopia. 
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Figure 2.1: Artemisia afra (adapted from Artemisia afra Herba, 1999.) 
 
Limited parts and only a few dosage forms of Artemisia afra are generally used. The 
leaves are mainly used but sometimes the roots are also used to treat the above-mentioned 
ailments. An infusion or decoction of A. afra leaves is generally prepared, often made 
syrupy with the addition of honey or sugar to mask the plant’s natural bitter taste. Plugs 
of fresh leaves may also be inserted in the nostrils to act as decongestant, or the leaves 
may be boiled in water and the fumes inhaled (Thring and Weitz, 2006; Van Wyk et al., 
2000). 
 
Artemisia afra is also one of the oldest, best known and most widely used of all the 
indigenous medicines in Southern Africa (Thring and Weitz, 2006). It has diverse and 
multiple uses, being mainly used for the treatment of coughs, colds, influenza, asthma, 
pneumonia as well as fever, loss of appetite, colic, headache, earache, malaria and 
intestinal worms (Thring and Weitz, 2006; Van Wyk et al., 2000). 
 
Indeed, Artemisia afra may have many useful pharmacological activities. Studies 
conducted on aqueous extracts of the plant have shown that it possesses bronchodilator 
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and anti-inflammatory activity and flavonoids are said to be responsible for some of these 
pharmacological activities of A. afra (Harris, 2002). In addition, A. afra may have 
narcotic analgesic and antihistaminic activities and the decongestant and antibacterial 
effects of its volatile oil are reputedly well known (Van Wyk et al., 2000). 
 
Finally, little information is available on the chemical constituents of Artemisia afra. It 
contains many phenolic compounds, which are mostly dominated by flavonoids. For 
instance, luteolin, kaempferol, apigenin, hesperetin, and quercetin have been detected in 
aqueous extracts of Artemisia afra (Muganga, 2004). In addition, A. afra contains volatile 
oil that mainly consists of 1, 8-cineole, α-thujone, camphor and borneol (Van Wyk et al., 
2000).  
 
2.1.2. Leonotis leonorus 
 
Leonotis leonorus (L. leonorus) belongs to the family of Lamiaceae and is known under 
different vernacular names such as wild dagga; Wilde dagga; lebake; umfincafincane and 
umhlahlampetu in English, Afrikaans, Zulu, Sotho, Xhosa and Shona, respectively. 
  
 
Figure 2. 2:  Leonotis leonorus (hhtp://www.plantzafrica.com/plant 
klm/leonotisleon.htm) 
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This attractive plant species is a shrub of two to five meters in height with thick, woody 
base and pale brown branches. All parts of the plant have a strong smell. The leaves are 
opposite each other on the stems that are long and narrow, toothed in the upper half and 
distinctly hairy. L. leonorus has bright orange, tubular flowers that are borne in 
characteristic rounded groups and are neatly arranged along the branch ends. The hairy 
flowers resemble lion’s ears, hence the name ‘leonorus’ which means lion’s ears (Van 
Wyk et al., 2000).   
 
L. leonorus has a wide natural distribution over large parts of South Africa and has 
become a popular garden plant. 
 
Numerous traditional uses have been reported for L. leonorus. It is used to treat colds, 
influenza, bronchitis, high blood pressure, headache, asthma and viral hepatitis.  In 
addition, it is used to treat boils, eczema, skin diseases, itching, muscular cramps, 
snakebite, other bites and stings (Van Wyk and Gericke, 2000). 
 
For L. leonorus, the leaves and stems are mainly used but sometimes also the roots. 
Decoctions of Leonotis leonorus are used externally for skin problems and internally, 
either by mouth or as an enema, to treat coughs, colds, fever, headaches and high blood 
pressure. In addition, leaf infusions have been used for asthma and viral hepatitis (Van 
Wyk and Gericke, 2000; Van Wyk et al., 2000; Thring and Weitz, 2006). Because it is 
only mildly narcotic, there are some doubts about early reports of the plant being smoked 
as a substitute for dagga. It has, however, been smoked for the relief of epilepsy. In 
Europe, this traditional phytomedicine is used for the symptomatic treatment of coughs in 
acute bronchial disease (Van Wyk and Gericke, 2000). 
 
In addition to volatile oil and flavonoids, Leonotis species contain several unusual 
diterpenoids (labdane type lactones). A typical example of these is marrubiin, which has 
been isolated from Leonotis leonorus (Van Wyk et al., 2000). 
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2.1.3. Mentha longifolia 
 
Mentha longifolia (M. longifolia) belongs to the family of Lamiaceae and is known as 
wild mint in English; ballerja and kruisement in Afrikaans; ufuthane lomhlange in Zulu; 
koena- ya- thaba in Sotho and inixina in Xhosa. 
 
 
Figure 2. 3:    Mentha longifolia (adapted from  
                       Mentha longifolia Herba, 1999.) 
    
 
Mentha longifolia is a perennial herb with creeping rhizomes below the ground and erect 
flowering stems of up to 0.8 meter in height. All parts of the plant are highly aromatic 
with a strong typical mint smell. The leaves appear opposite each other in pairs along the 
stems, which are square in cross-section. Small white or pale purple flowers are borne in 
elongated clusters on the tips of the stems. Several different subspecies of M. longifolia 
are known, of which the best known one in South Africa is the subspecies capensis (Van 
Wyk et al., 2000). 
 
M. longifolia is widely distributed in South Africa but is only found in wet places. 
 
M. longifolia is used for many different ailments, mainly for coughs, colds, asthma, and 
other respiratory ailments. It has also been used to treat headaches, fevers, indigestion, 
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flatulences, and hysteria, painful menstruations, delayed pregnancy and for urinary tract 
infections. Externally, it has been used to treat wounds and swollen glands (Van Wyk et 
al., 2000). 
 
M. longifolia has been reported to be a diaphoretic and antispasmodic. Its volatile oils 
possess decongestive, antibacterial and antiseptic effects (Van Wyk et al., 2000). 
 
The leaves are mostly used but sometimes the stems and the rhizomes are also used. 
Infusions or decoctions of the leaves of M. longifolia are drunk or administrated as 
enemas. In addition, crushed leaves may be inserted in the nostrils for the relief of 
headache or placed under the bedding to reduce breathing problems (Van Wyk and 
Gericke, 2000; Van Wyk et al., 2000). 
 
The composition of the active ingredients of the plant is known to vary considerably at 
different localities but no information appears to be available on South African plants 
(Van Wyk et al., 2000). The species contains hesperidin and several other flavonoids 
such as the glycosides of tricetin, vicenin, luteolin and isoorientin as well as aglycones 
such as luteolin (Sharaf et al., 1999; Ghoulami et al., 2001). 
 
2.1.4. Common features of the three plants 
 
Artemisia afra, Leonotis leonorus and Mentha longifolia are among the most widely used 
medicinal plants in South African traditional medicine for the treatment of many 
diseases. One claimed use they have in common is that of the treatment of asthma 
(Thring and Weitz, 2006). Appropriate validation of these claimed uses, including the 
treatment of asthma, is however lacking and requires the proper scientific study of these 
medicinal plants.  
 
Studies conducted on Artemisia afra, Leonotis leonorus and Mentha longifolia have 
reported that they possess smooth muscle relaxant properties (Harris, 2002; Erasmus, 
2004). Luteolin, one of the flavones found in these plants, has been shown to possess a 
 
 
 
 
 9
tracheal muscle relaxant effect that is not mediated via any of the following mechanisms: 
activation of β-adrenoceptor, activation of adenylate cyclase or guanylate cyclase nor the 
opening of adenosine triphosphate-sensitive potassium channels. The effect is also 
unrelated to the nitric oxide formation or the neuropeptides (Ko et al., 2005). The 
relaxant effect of luteolin may rather be mediated via the inhibition of cyclic adenosine 
monophosphate (cAMP)- and cyclic guanosine monophosphate (cGMP)-
phosphodiesterases, and the subsequent increase of these two cyclic nucleotides (Ko et 
al., 2005). Because they contain luteolin and/or other flavonoids, the anti-asthmatic effect 
of Artemisia afra, Leonotis leonorus and Mentha longifolia may therefore be mediated 
via phosphodiesterase inhibition.  
 
2.2. Asthma and Phosphodiesterases 
2.2.1. Asthma 
 
Asthma is an inflammatory disease of the airways characterized by recurrent reversible 
airway obstruction and hyperresponsiveness to non-specific stimuli such as air pollutants, 
cold air, exercise, allergens and infections (Das, 2003). Each of these stimuli evokes 
airway narrowing indirectly through the release of mediators from a variety of effector 
cells, including inflammatory cells and epithelial cells (Wong and Koh, 2000; Chung, 
2006).  
 
Some of the different inflammatory cells involved in asthma are predominant in 
asthmatic inflammation. Cumulative findings support the notion that T- helper 2 (Th 2) 
cells, B cells, mast cells and eosinophils contribute to the chronic inflammation of the 
airways and that mediators such as histamine, prostaglandins and leucotrienes contract 
airway smooth muscle, increase microvascular leakage, increase airway mucus secretion 
and attract other inflammatory cells (Chung, 2006; Sun et al., 2006). Asthma is also a 
chronic inflammatory disease, with inflammation persisting over many years in most 
patients. 
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Inhaled β2 adrenergic receptor agonists and corticosteroids have represented the mainstay 
of the therapeutic management of asthma for at least 25 years. Beta-2 adrenoceptor 
agonists, which inhibit bronchoconstriction, would provide little more than symptomatic 
relief, while the anti-inflammatory effect of glucocorticoids may affect disease 
progression (Wenzel, 1998; Piaz and Giovannoni, 2000). 
 
2.2.1.1.  Current treatment of asthma 
 
There are two main categories of anti asthma drugs: the bronchodilators and the anti -
inflammatory agents. 
 
2.2.1.1.1.  Bronchodilators drugs 
 
Three types of bronchodilators are used to treat asthma, namely the β2- adrenoceptor 
agonists, the xanthines and the muscarinic receptor antagonists. 
 
Drugs that act as selective β2- adrenoceptor agonists are the first line bronchodilator 
agents for the treatment of asthma. The main actions of β2- adrenoceptor agonists are 
bronchial smooth muscle relaxation, inhibition of mediators released from inflammatory 
cells, inhibition of cholinergic neurotransmission, reduced vascular permeability and 
increased mucociliary clearance (Rang et al., 2003). Considering their duration of action 
following inhalation of conventional doses, β2- agonists can be divided into three broad 
groups: (a) the catecholamines, such as rimiterol, which have a very short action of 1-2 h; 
(b) those described as short acting, such as salbutamol and terbutaline, which are active 
for 3-6 h, although fenoterol may be slightly shorter acting and (c) the long-acting β-
agonists salmeterol and formoterol, which cause bronchodilation for at least 12 h (Chung 
and Barnes, 1993). Finally, the β2- adrenoceptor agonists are usually given by inhalation 
of aerosol, powder or nebulised solution, but some may also be given orally or by 
injection (Rang et al., 2003). 
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The xanthine bronchodilator group constitutes three pharmacologically active, naturally 
occurring methylxanthines, viz. theophylline, theobromine and caffeine. Theophylline (1, 
3-dimethylxantine) is the most frequently employed in clinical medicine and can also be 
used as theophylline ethylenediamine, known as aminophylline. Theophylline has 
bronchodilator action, but it is rather less effective than the β2- adrenoceptor agonists. 
Despite their widespread use, the mechanisms of action of the xanthine drugs in asthma 
are still unclear. The relaxant effect on bronchial smooth muscle is attributed to the 
inhibition of the phosphodiesterase (PDE) isoenzymes, with a resultant increase in 
cAMP. However, the concentrations necessary to inhibit the isolated enzyme greatly 
exceed the therapeutic range (Rang et al., 2003). Finally, the xanthine drugs are usually 
given orally in sustained-release preparations. Aminophylline can also be given by slow 
intravenous injection of a loading dose followed by intravenous infusion (Rang et al., 
2003). 
 
Finally, the main muscarinic receptor antagonist that is specifically used in asthma is 
ipratropium bromide. It relaxes bronchial constriction caused by parasympathetic 
stimulation, which occurs particularly in asthma induced by irritant stimuli and in allergic 
asthma (Rang et al., 2003). Ipratropium bromide inhibits the augmentation of mucus 
secretion that occurs in asthma and may increase the mucociliary clearance of bronchial 
secretions. Generally, ipratropium bromide is given by aerosol inhalation. 
 
2.2.1.1.2  Anti-inflammatory agents 
 
Two different types of anti-inflammatory drugs are used in the treatment of asthma: the 
glucocorticoids that are mainly used in chronic conditions and sodium cromoglycate, 
which is thought to reduce bronchial hyper-reactivity. 
 
Steroids are the most effective therapy currently available for asthma and inhaled 
glucocorticoids have become the mainstay of therapy for patients with chronic disease. 
Glucocorticoids are highly effective because they block many of the inflammatory 
pathways activated in asthma (Rang et al., 2003). They exert their effects by binding to 
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glucocorticoids receptors (GRs), which are localized in the cytoplasm of target cells and 
therefore may control inflammation by inhibiting many aspects of the inflammatory 
process. The main glucocorticoid compounds used are beclomethasone dipropionate, 
budesonide and fluticasone propionate, which are given by inhalation with a metered-
dose inhaler, the full effect being attained only after several days of therapy (Rang et al., 
2003). 
 
Cromoglicate and the related drug nedocromil sodium are not bronchodilators. They do 
not have any indirect effects on smooth muscle, nor do they inhibit the actions of any of 
the known smooth muscle stimulants. If given prophylactically, they can reduce both the 
immediate and the late-phase asthmatic responses and reduce bronchial hyper-reactivity. 
They are effective in antigen-induced, exercise-induced and irritant-induced asthma. 
Cromoglicate is only given by inhalation, either as an aerosol, as a nebulised solution or 
in powder form (Rang et al., 2003). 
 
2.2.1.1.3 Other drugs 
Leukotriene inhibitors and phosphodiesterase 4 inhibitors are the new classes of drugs 
for the treatment of asthma.  
Leukotriene modifiers are an entirely new class of asthma treatment, which have entered 
clinical practice in 1996-7 in several countries including Britain, Japan, and the United 
States (Sampson and Holgate, 1998). Leukotriene synthesis inhibitors and cysteinyl 
leukotriene receptor antagonists constitute the two types of leukotriene modifier 
(Sampson and Holgate, 1998; Scow et al., 2007). Both are used to block the 
bronchoconstrictor and pro-inflammatory activity of cysteinyl leukotrienes within the 
asthmatic airway (Sampson and Holgate, 1998). The leukotriene receptor antagonists 
include zafirlukast and montelukast ; zileuton is the only leukotriene synthesis inhibitor 
(Scow et al., 2007). In the treatment of asthma, randomized controlled trials have shown 
leukotriene inhibitors to be more effective than placebo but less effective than inhaled 
corticosteroids or long-acting beta2 agonists (Scow et al., 2007). Although their anti-
inflammatory effects are likely to be less pronounced than those of high dose 
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corticosteroids, their excellent side effect profile and their availability as oral drugs are 
likely to ensure that compliance with treatment is substantially better than for inhaled 
corticosteroids (Sampson and Holgate, 1998). While interrupting the leukotriene pathway 
offers a new opportunity for treating asthma, the position of such drugs in the asthma 
armamentarium has not yet been firmly established. Further effectiveness studies are 
needed to determine the true value of this oral anti-asthma treatment (Sampson and 
Holgate, 1998). 
 
Over the last decade, considerable attention has focused on cyclic nucleotide 
phosphodiesterase isozymes 4 as a molecular target for drugs useful for the treatment of 
pulmonary diseases (Torphy et al., 1999). From the beginning of 1990s, growing interest 
was devoted to identifying selective PDE 4 inhibitors and more recently, the critical role 
of various signal transduction pathways in mediating inflammatory cell responses has 
been confirmed. In general, an increase in the level of the intracellular second messenger 
cAMP is usually associated with the suppression of immune and inflammatory cells (Piaz 
and Giovannoni, 2000). 
 
 The type 4 cAMP specific isoenzyme, which was identified in 1985, is particularly 
abundant in the brain and immunocompetent cells. In the eosinophils, which are 
considered the effectors “par excellence” of asthma, PDE 4 is the only isoform present 
(Piaz and Giovannoni, 2000). 
 
Inhibition of PDE 4 in all these cells produces a marked reduction of inflammatory 
immunomodulatory response. Moreover, in vivo PDE 4 inhibitors reduce the tone of 
bronchial smooth muscle and produce bronchodilation induced by a variety of agents 
such as histamine, leukotrienes D4 (LTD 4), carbachol or methacholine. Taken together 
these data suggest a possible therapeutic utility of PDE 4 inhibitors as anti-inflammatory 
and immunomodulatory agents (Piaz and Giovannoni, 2000). 
 
Traditionally, PDE 4 inhibitors are classified into three main chemical classes: 
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1.  Catechol ethers, in which a wide variety of flexible molecules of inhibitors 
structurally related to rolipram are grouped; 
2.  Quinazolinediones, in which are classified the PDE 4 inhibitors structurally 
related to nitraquazone; 
3.  Xanthines, to which theophylline belongs. 
 
The growing interest in the development of antiasthma drugs displaying both 
bronchodilatory and anti-inflammatory activity is motivated by reasons such as the 
adverse effects arising with the chronic administration of glucocorticoids, the systemic 
side effects such as tachycardia, palpitation and headache observed with inhaled β2- 
adrenoceptors and, finally, a possible reduced inhaled drug delivery due to airway 
obstruction subsequent to disease progression. There is a need for novel drugs that are 
able to compete with and, perhaps replace corticosteroids and β2-adrenoceptor agonists in 
the therapeutic management of asthma (Piaz and Giovannoni, 2000). Since inflammation 
and bronchoconstriction constitute the major pathological features of asthma, the 
inhibition of PDE enzymes represents a promising therapeutic target (Lacombe et al., 
2006). 
 
2.2.2.  Phosphodiesterases (PDEs) 
 
The phosphodiesterases (PDEs) are a superfamily of metalloenzymes which inactivate 
the intracellular second messenger cyclic nucleotides 3’, 5’-cyclic adenosine 
monophosphate (cAMP) and 3’, 5’-cyclic guanosine monophosphate (cGMP) (see figure 
2.4) by catalyzing the hydrolytic cleavage of the 3’-phosphoester bond to form the 
corresponding 5’-nucleotide inactive product (Chung and Barnes, 1993; Piaz and 
Giovannoni, 2000; Chung, 2006). Inhibition of these enzymes leads to an increase in the 
intracellular level of cAMP and cGMP.  
 
The understanding of PDE inhibition began with a series of publications in the late 1950s 
by Sutherland and Rall who described the properties of a cyclic adenine ribonucleotide 
later called cAMP (Essayan, 1999).  More recently, many studies on the physiological 
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role of cAMP and cGMP have described their mechanism in the regulation of important 
cellular functions such as secretion and contraction (Piaz and Giovannoni, 2000). 
 
2.2.2.1.  Molecular mechanisms of cyclic nucleotides action 
 
                              
          cAMP       cGMP 
Figure 2.4: chemical structures of the cyclic nucleotides c AMP and c GMP 
 
Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) 
are ubiquitous intracellular second messengers that mediate the physiologic response to a 
host of hormones, neurotransmitters, autocoids and drugs. Cyclic nucleotides, especially 
cAMP, have important regulatory roles in virtually all cell types involved in the 
pathophysiology of asthma, as shown in figure 2.5 (Torphy, 1998; Essayan, 1999; Piaz 
and Giovannoni, 2000). 
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Figure 2.5: Proposed beneficial actions of cyclic AMP. The downward-
pointing arrows represent inhibition and the upward-pointing 
arrow represents stimulation. Listed at the bottom of the figure are 
specific inflammatory cell functions inhibited by cyclic AMP. 
Abbreviations: AWSM 5 airway smooth muscle; eNANC 5 
excitatory nonadrenergic noncholinergic neurotransmission; 
iNANC 5 inhibitory nonadrenergic noncholinergic 
neurotransmission; IL 5 interleukin; LT 5 leukotriene; IFNg 5 
interferon-gamma; O2 2 5 superoxideanion; PAF 5 platelet-
activating factor. (Torphy et al., 1999) 
 
Cyclic AMP broadly suppresses the activity of virtually all immunocompetent cells. In 
addition, it induces airway smooth muscle relaxation, suppresses smooth muscle 
mitogenesis and has beneficial modulatory effects on the activity of pulmonary nerves 
(De Gonzales et al., 2004). 
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Figure 2.6: Cyclic AMP versus cyclic GMP second messenger pathways. Key PDE 
isozymes responsible for regulating cyclic AMP or cyclic GMP content in 
immunocompetent cells and airway smooth muscle are in bold face. 
Abbreviations: cAMP 5 cyclic AMP; cGMP 5 cyclic GMP; EDRF 5 
endothelium-derived relaxant factor (i.e., NO); iNANC 5 inhibitory 
nonadrenergic noncholinergic nerves; PKA 5 cAMP-dependent protein 
kinase; PKG 5 cGMPdependent protein kinase; NVD 5 nitrovasodilators 
(Torphy, 1998) 
 
Cyclic AMP and cyclic GMP are formed from ATP and GMP by the catalytic action of 
adenylyl cyclase and guanylyl cyclase, respectively (Torphy, 1998; Essayan, 1999). As 
the intracellular concentrations of the cyclic nucleotides rise, they bind to and activate 
their target enzymes, protein kinase A (PKA) and protein kinase G (PKG). These protein 
kinases phosphorylate substances (e.g., ion channels, contractile proteins, transcription 
factors) that regulate key cellular functions. Phosphorylation alters the activity of these 
substrates, and thus changes cellular activity, as shown in figures 2.6 and 2.7 (Chung and 
Barnes, 1993; Torphy, 1998). 
 
Studies with airway smooth muscle suggest that activation of cAMP -dependent protein 
kinase can induce relaxation by (1) increasing Ca2+-sequestration or extraction, (2) 
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preventing Ca 2+ influx, (3) hyperpolarizing cell membranes by activating Na+, K+-
ATPase or opening large-conductance K+ channels, or (4) direct modulation of 
contractile protein (Spina et al., 1998). On the other hand, inhibition of inflammatory cell 
activity following activation of cAMP-dependent protein kinase may be mediated via (1) 
inhibition of Ca2+ influx and/or release, (2) stimulation of Ca2+ extrusion, (3) direct 
inhibition of mediator release by a mechanism that is independent of changes in Ca2+ 
levels, and (4) by interference with the production of certain cytokines. Moreover, it is 
unlikely that the functional response of any individual cell to an increase in cAMP 
accumulation is the result of a single biochemical mechanism. Instead, cell activation is 
likely to be regulated by the simultaneous or sequential activation of several cAMP – 
dependent pathways (Chung and Barnes, 1993). 
 
                 
Figure 2.7:  Cyclic nucleotide homeostasis. Abbreviations: cAK, cAMP-dependent 
protein kinase; and cGK, cGMP-dependent protein kinase (Essayan, 1999) 
 
The mechanism(s) by which cGMP relaxes airway smooth muscle is thought to be 
analogous to that of cAMP. There is a corresponding decrease in protein kinase activity 
as cAMP or cGMP are inactivated by PDEs. In addition, phosphoprotein phosphatases 
dephosphorylate substrates and cellular activity return to normal. Obviously, altering the 
rate of cyclic nucleotides formation or degradation will thus change the activation state of 
these pathways (Chung and Barnes, 1993; Essayan, 1999). The elevation of the 
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intracellular levels of cyclic nucleotides by inhibition of phosphodiesterase isozymes 
therefore represents a useful strategy for eliciting a variety of pharmacological effects 
(Piaz and Giovannoni, 2000). 
 
2.2.2.2  Phosphodiesterase isozymes  
 
As already mentioned, the understanding of PDE inhibition began with a series of 
publications in the late 1950s by Sutherland and Rall (Essayan, 2000). The anti-
inflammatory potential of PDE inhibitors was first clearly demonstrated in a 
series of reports by Lichtenstein and colleagues in the early 1970s (Essayan, 2000). 
These findings indicated a presence of a complex family of PDE enzymes and 
suggested the potential utility of selectivity in a design of PDE inhibitors (Essayan, 
2000). 
 
It is now recognized that 11 families of PDEs exist, the major families being designated 
by Arabic numerals (Barber, 2004). Most of the families include more than one product 
as well as multiple splice variants. The GenBank nomenclature for PDEs includes the 
species and gene family designation (e.g. HSPDE4 for Homo sapien PDE isozyme 4) 
followed by the gene product or “subtype” (e.g. HSPDE4D) and the splice variant (e.g., 
HSPDE4D3) (Torphy, 1998). The families are also named according to the identity of the 
inhibitors (e.g., cyclic AMP) or the endogenous activators such as calmodulin (Torphy, 
1998). 
 
For some isoenzymes, endogenous regulators such as Ca 2+ and calmodulin, co-factors 
such as Mg 2+ and possibly Zn2+ and synthetic selective inhibitors such as milrinone, 
siquazodan selective inhibitors of PDE 3, rolipram for PDE 4, zaprinast and sildenafil for 
PDE 5, are known (Piaz and Giovannoni, 2000). 
 
Each family of phosphodiesterases is encoded by distinct genes (e.g., A, B, C or D for 
PDE 4) and within each of them, there are multiple isoforms expressed. There are at least 
44 distinct human PDEs (Piaz and Giovannoni, 2000).  
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Amongst the PDEs, with respect to substrate, PDE 4, PDE 7 and PDE 8 are specific for 
cAMP, whereas PDEs 5, 6, 9 are selective for cGMP. The isoenzyme PDE 3 binds cAMP 
and cGMP with similar affinity, but it hydrolyses cGMP relatively poorly. At the same 
time, PDEs 1 and 2 hydrolyze both cyclic nucleotides, although with PDE 1, the relative 
efficiencies vary with isozymes subtypes (Perry and Higgs, 1998).  
 
Over the last decade, compounds that display a marked degree of selectivity for one PDE 
isozyme over another have become available and have fuelled the hypothesis that PDE 
inhibitors could have therapeutic potential in a number of inflammatory diseases 
including asthma (Kelly et al., 1996). Furthermore, isoenzyme selective PDE inhibitors 
might be associated with reduced incidence of side effects compared to that of the non- 
selective drugs (e.g. theophylline) that indiscriminately inhibit all PDE isoenzymes 
(Kelly et al., 1996, Beasley et al., 1998). Indeed a vigorous pursuit of selective PDE 4 
inhibitors has resulted.  
 
2.2.2.2.1 The PDE 4 Family 
 
The PDE 4 family is currently the largest and four genes encode the PDE 4 isoenzyme. 
This group of isoenzymes is widely expressed in many tissues. However, very little 
information has been published to show exactly which gene is expressed in which tissue, 
or the localization of the splice variant. A number of tissues and cell types have received 
particular attention recently, including the lung lymphocytes. PDE 4 is likely to play a 
particular important role in inflammatory and immunomodulatory cells (Beavo, 1995). In 
addition, it is the predominant PDE in inflammatory cells, including mast cells, 
eosinophils, neutrophils, T cells, macrophages and in structural cells such as sensory 
nerves and epithelial cells relevant to the pathogenesis of asthma. PDE 4 inhibitors block 
the hydrolysis of cAMP, leading to elevation of intracellular cAMP levels and subsequent 
suppression of inflammatory activity and decrease of mediator release from these 
inflammatory cells (Ko et al., 2004; Chung, 2006). 
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2.2.2.2.2.  Methods to measure the PDE inhibitory activity of compounds 
 
Several methods are mentioned in the literature for the measurement of the PDE –
inhibitory activity of compounds. These include the BIOMOL GREENTM 
phosphodiesterase assay, the method of Cook et al. (1995), the High Efficiency 
Fluorescence Polarization and the Phosphodiesterase on Flash Plate® from Perkin Elmer. 
These methods are discussed below.  
 
2.2.2.2.2.1. The BIOMOL GREEN TM Phosphodiesterase assay 
 
The BIOMOL Cyclic Nucleotide Phosphodiesterase (PDE) Assay is a colorimetric, non-
radioactive assay designed in a microplate format that may be used to screen inhibitors 
and modulators of cyclic nucleotides (www.biomol.com). 
 
The basis for the assay is the cleavage of cAMP or cGMP by a cyclic nucleotide 
phosphodiesterase. The 5’-nucleotide released is further cleaved into the nucleoside and 
phosphate by the enzyme 5’- nucleotidase. The phosphate released due to enzymatic 
cleavage is quantified using BIOMOL GREENTM reagent, which is made of ammonium 
molybdate and malachite green.  
 
The phosphate released reacts with ammonium molybdate in an acidic solution to form 
the phosphomolybdic acid. The molybdenum formed is then reduced by the malachite 
green in the phosphomolybdate to give a blue colour (Cogan et al., 1999; Wong, 2000). 
Using a spectrophotometer or a micro-titer plate reader the absorbance (at wavelength 
620 to 670 nm) of this complex can easily be quantified (Simonovic et al., 2004). The 
amount of phosphate detected is indirectly proportional to the PDE inhibitory activity of 
the compound tested. 
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The BIOMOL GREENTM phosphodiesterase assay is a non-radioactive highly sensitive 
method. It uses a 1-step reagent for phosphate detection and is convenient and suitable 
for microplate or cuvette assay. 
Since the BIOMOL GREENTM is a highly sensitive phosphate detection method, the 
effective removal of phosphate from the extracts to be tested and/or the labware and 
reagents solutions used is recommended to avoid any increase in the background 
absorbance of the assay (www.biomol.com). 
 
2.2.2.2.2.2.  Method of Cook et al. (1995) 
 
Homogeneous radiometric assays, such as scintillation proximity assays (SPA, 
Amersham Biosciences) and Flashplate technology (NEN/Perkin Elmer) enable the direct 
detection of [125I]-labelled cAMP or [3H] –labelled cAMP once it is in close proximity to 
a solid scintillant surface. 
 
The method of Cook et al. (1995) is based on the breakdown of [3H] cAMP by PDE to 
the corresponding labelled nucleoside 5´-monophosphate, which is subsequently 
dephosphorylated by alkaline phosphatase to give the labelled nucleoside (Ko et al, 
2005). In tests of enzyme inhibition, the reaction mixture contains various concentrations 
of the inhibitor and the radioactivity of the labelled nucleoside is determined by liquid-
scintillation counting in ACS II scintillant (Amersham). 
 
These radiometric technologies are to some extent presently being superseded by safer 
non-radiometric read-outs, which might be cheaper and more readily miniaturized. 
 
2.2.2.2.2.3.  Phosphodiesterase Assays on FlashPlate® Microplates 
 
The Phosphodiesterase Assays on FlashPlate® Microplates method involves adding a 
source of phosphodiesterase and [125I]-labelled cAMP or [125I]-labelled cGMP to a 
FlashPlate well that contains an antibody to either cAMP or cGMP. The 
phosphodiesterase will catalyze the breakdown of the [125I]-labelled cAMP or [125I]-
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labelled cGMP to their corresponding 5’nucleotides. The antibody will not bind to the 
catalyzed product, therefore the decrease in the amount of the [125I] cAMP or [125I] cGMP 
will be detected (Kasila, 2000). 
To screen for inhibitors of phosphodiesterase, a source of phosphodiesterase, [125I] cAMP 
or [125I] cGMP, and the test compounds are added to a FlashPlate well as explained 
above. If the compound is found to be an inhibitor of phosphodiesterase, the catalyzed 
breakdown of cAMP or cGMP will not occur, therefore, a decrease in the amount of [125I] 
cAMP or [125I] cGMP will not occur (Kasila, 2000). 
 
The Flashplate technology offers distinct advantages over more traditional methods in 
terms of convenience (stimulation and detection can be carried out in the same well), 
time and reproducibility. Although advances are still being made in this area for example, 
with the development of Red-Shifted Plates that aim to minimize compound artifacts, the 
radiometric technologies are however to some extent being superseded by safer non-
radiometric read-outs, as mentioned above in the method of Cook, et al., (De Jong et al., 
2005). 
 
2.2.2.2.2.4. The High-Efficiency Fluorescence Polarization (HEFPTM) 
Phosphodiesterase assay 
 
The fluorescence polarization (FP) measures the change in rotational speed of a ligand 
during its excited lifetime upon binding to its receptor. In the (HEFPTM) PDE assay a 
fluorescent-labeled ligand is excited by polarized light and the polarization of the emitted 
light determined. The emitted light is largely depolarized in the presence of a small and 
therefore rapidly rotating ligand, while rotational speed and thus depolarization is 
significantly reduced when the ligand is bound to a receptor (De Jong et al., 2005).  
 
The HEFP Phosphodiesterase assay measures the activity of PDEs that use cAMP or 
cGMP as substrates. The fluorescein (fluorophore)-labeled derivatives of c AMP (FL-
cAMP) and cGMP (FL-cGMP) are hydrolyzed by PDE, and bind to the Binding Reagent. 
In this bound form, the fluorescence is highly polarized. This assay is designed to 
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determine an increase in activity of cyclic nucleotide-dependent PDE in solution 
(www.moleculardevices.com). 
 
The HEFP Phosphodiesterase assay is a sensitive, non-radioactive, homogenous and 
rapid assay and requires 1 labelling step. However, the FP technique displays a number of 
disadvantages, like the potential for compound interference. Data from previous studies 
indicate that some artifacts, at least up to a final assay concentration of 10 μM, were 
observed using the fluorescein-labelled cAMP and that there was a lack of precision at 
low nanomolar concentrations. As for all other similar technologies, the sensitivity of FP 
is dependent on the affinity of the ligand, the quantity of the receptor and the intensity of 
the fluorophore (www.moleculardevices.com). 
 
2.2.2.2.3. Current problems associated with PDE 4 inhibitors 
 
One of the major issues associated with the development of PDE 4 inhibitors has been 
their propensity to induce emesis. This observation has been reported on several 
prototypical compounds (Lacombe et al., 2006). Rolipram, a highly selective first 
generation PDE 4 inhibitor caused high levels of nausea and vomiting. This side effect is 
an important cause for drug unacceptability amongst patients, particularly for a 
medication that has to be taken on a long -term basis. There is, therefore, a need to 
develop PDE 4 inhibitors devoid of these side effects.  
 
A. afra, L. leonorus and M. longifolia contain flavonoids that have been reported to 
inhibit the PDEs and to have mild, if any, side-effects when consumed medicinally (Chi 
et al., 2001). By containing such flavonoids these plant species may thus, also possess a 
PDE inhibitory activity and be devoid of the above-mentioned side-effects. 
 
2.3. Flavonoids 
 
Flavonoids are naturally occurring polyphenolic compounds with a wide distribution in 
the plant kingdom. They are found in regularly consumed foods (e.g. vegetables and 
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fruits) and beverages like tea and red wine. Many of the 4000 different flavonoids known 
to date are part of the regular human diet (Havsteen, 2002). 
 
Flavonoids are composed of two aromatic rings linked through three carbon atoms that 
form an oxygenated heterocyclic ring. Variations on the basic structure of flavonoids 
yield different classes of flavonoids. They are usually subdivided according to their 
chemical structure into flavanols, anthocyanidins, flavones, flavanones and chalcones 
(Orallo et al., 2004). 
 
2.3.1 Chemistry and classification 
 
Flavonoids are a group of low-molecular-weight polyphenolic substances. They are 
formed from the combination of derivatives synthesized from phenylalanine (via the 
shikimic acid pathway) and acetic acid. 
 
The structure of the flavonoids is based on the flavonoid nucleus (Fig. 2.8), which 
consists of three phenolic rings referred to as the A, B, and C rings. The benzene ring (A) 
is condensed with a six-member ring (C), which in the 2-position carries a phenyl 
benzene ring (B) as a substituent. Ring C may be a heterocyclic pyran, which yields 
flavanols (catechins), and anthocyanidins, or pyrone, which yields flavonols, flavones, 
and flavanones. The term 4-oxo-flavonoid is often used to describe flavonoids, such as 
flavanols (catechins), flavanones, flavonols and flavones, which carry a carbonyl group 
on C-4 of ring C (figure 2.8). The chemical nature of the flavonoids depends on structural 
class, degree of hydroxylation, other substitutions, conjugations, and degree of 
polymerization. In plants, the flavonoids are relatively resistant to heat, oxygen, dryness 
and moderate degrees of acidity, the molecule depends on the nature of the hydroxyl 
group attached to C-3 of ring C. The absence or glycosylation of this hydroxyl group 
results in high photostability of the molecule (Aisling and O’Brian, 2002). 
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Figure 2. 8:     (a) Flavan nucleus and (b) 4-oxo-flavonoid nucleus (Aisling and   
O’Brian, 2002) 
 
The basic structure of the flavonoid nucleus allows for a multitude of substitution 
patterns in the A, B, and C rings, resulting in various subgroups. The flavonoids are 
divided into classes according to their oxidation level on the C-ring, which include 
anthocyanidins, flavanols (catechins), flavones, flavonols, flavanones, and isoflavonoids, 
4, 5 among others. Flavones and flavonols have been identified in almost all plants; the 
ones found most frequently being those with B-ring hydroxylation in the C-3 and C-4 
positions (Havsteen, 2002). 
 
2.3.2   Flavonoid Glycosides 
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The structures of flavonoids differ greatly within the major classifications and 
substitutions include glycosylation, hydrogenation, hydroxylation, malonylation, 
methylation, and sulfation. Flavonoid molecules not attached to sugar moieties are 
referred to as the aglycone form, whereas flavonoid molecules with sugar moieties are 
called flavonoid glycosides (Markham, 1982). 
 
Except for catechins, flavonoids rarely occur in plants as aglycones, the most frequently 
occurring forms are the glycoside derivatives in plants. Glycosylation at positions 5, 7 
and 9 increases the polarity of the flavonoid molecule, which is necessary for storage in 
plant cell vacuoles. Flavonols and flavones occur in food usually as o-glycosides. D-
glucose is the most usual sugar residue, but other carbohydrate substitutions include 
arabinose, galactose, glucorhamnose, lignin, L-rhamnose, and xylose (Markham, 1982).  
 
2.3.3  Biological activities of flavonoids 
 
Flavonoids possess various biological/pharmacological activities including antioxidant, 
antitumour, antiangiogenic, anti-inflammatory, antiallergic and antiviral properties. 
Flavonoids have also been reported to inhibit xanthine oxidase, protein kinase C and PDE 
(Ko et al., 2004; Havsteen, 2002). Within the last decade, reports on flavonoid activities 
have been predominantly associated with anti-proliferative activity and enzyme inhibition 
or induction. 
 
2.3.4  Analytical techniques suitable for the determination of flavonoid 
levels in plant material 
 
Several methods are used to separate, purify, identify and quantitate flavonoids in plant 
material. The methods include many steps such as separation, purification and 
identification of different constituents that may be present in the plants. Depending on the 
form of flavonoids (aglycone or glycoside), different solvents can be used to extract 
them. Flavonoids possessing a number of un-substituted hydroxyl groups or sugar are 
polar and generally soluble in polar solvents such as ethanol, methanol, dimethyl 
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sulphoxide and water. Less polar aglycones such as flavonols and flavones are more 
soluble in non-polar solvents such as ether and chloroform (Markam, 1982). 
 
Some colorimetric methods are used to determine the total flavonoids contents in plants. 
For instance, the aluminium chloride method that is based on the formation of aluminium 
chloride-flavonoid aglycone complex is commonly used to determine the total flavonoid 
levels in plants. 
 
High performance liquid chromatography (HPLC) is being increasingly utilized for the 
screening of drugs, vitamins, and natural products. HPLC is a sensitive, rapid, and 
economical technique, which can be used in the separation, identification and 
quantification of flavonoids in plant extracts (Springfield et al., 2005). In HPLC assays, 
various proportions of solvents such as water-methanol, water-methanol-acetic acid or 
formic acid and water - acetonitrile have been reported for the elution of flavonoids such 
as luteolin and hesperetin (Markham, 1980). 
 
2.3.5  Examples of flavonoids in Artemisia afra, Leonotis leonorus and 
Mentha longifolia  
 
 
Artemisia afra, Leonotis leonorus and Mentha longifolia contain several flavonoids such 
as luteolin, apigenin, hesperetin, hesperidin, and quercetin. The flavonoids most likely to 
be found in Artemisia afra, Leonotis leonorus and Mentha longifolia are luteolin and 
hesperetin. These two compounds are thus ideal candidates as marker compounds for 
studies to assess their PDE-inhibitory activity.  
 
2.3.5.1. Luteolin 
 
Luteolin (5,7,3’, 4’tetrahydrooxy flavone) is a flavone widely found in glycoside form in 
some plants, such as celery, green pepper, perilla leave, chamomile tea, and as an 
aglycone in perilla seeds (Ko et al., 2005). 
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Figure 2. 9: Chemical structure of luteolin (Ko et al., 2005) 
 
Luteolin has been attributed with anti-inflammatory, anti-allergic, antimutagenic, 
antiplatelet aggregation, anticancer and antioxidant properties (Kim et al., 2002; Das, 
2003). 
 
The anti-inflammatory and anti-allergic properties of luteolin are attributed to the 
attenuation of tumor necrosis factor (TNF)-α production and intracellular adhesion 
molecule-1 expression and the abolition of infiltration of leukocytes in the lung and liver 
of lipopolysaccaride – treated mice. Earlier studies showed that luteolin was effective in 
reducing the release of histamine, leukotrienes, prostaglandins D2 and other mediators 
from various effector cells including mast cells in vitro (Das et al., 2003). In addition, Ko 
et al. (2005) have demonstrated that luteolin possess an effective inhibitory activity on 
PDE 1 to 5. Luteolin has also been shown to possess a tracheal muscle relaxant effect that 
may be due to its inhibitory effect on cyclic adenosine monophosphate (c-AMP) 
phosphodiesterase (Ko et al., 2004). 
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Because of this profile of action, luteolin could be used as a lead molecule to identify an 
effective anti-asthma therapy or as a means to identify novel anti-asthma targets (Ko et 
al., 2004). 
 
 
2.3.5.2 Hesperetin 
 
Hesperetin (3’, 5, 7-trihydroxy-flavanone) is mainly present in citrus fruits and also in 
many plants.  
 
 
 
Figure 2.10: Chemical structure of  hesperetin 
                        (Orallo et al., 2004) 
 
Hesperetin displays a number of biological effects. It has been shown to inhibit 
chemically induced mammary, urinary bladder, and colon carcinogenesis in laboratory 
animals. Hesperetin also possesses some antioxidant activities, although this activity is 
poorer compared with many other polyphenols. Other possible effects of hesperetin are 
on lipid metabolism. Hesperetin has been reported to regulate apolipoprotein B secretion 
by HepG2 cells, possibly through inhibition of cholesterol ester synthesis, and to inhibit 
3-hydroxy-3-methylglutaryl-coenzyme A reductase and acyl coenzyme A: cholesterol O-
acyltransferase in rats (Erlund, 2004). In addition, hesperetin has been shown to possess 
inhibitory effect on PDE 4 activity that plays an important role in asthma. Hesperetin 
may therefore reduce the bronchoconstriction and airways hyperreactivity by affecting a 
number of pathways involved in asthma pathogenesis (Ko et al., 2004; Orallo et al., 
2004). 
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CHAPTER 3 
WORK PLAN 
 
 3.1 Objectives 
 
The specific objectives for this study were to: 
(i) Investigate whether Artemisia afra, Leonotis leonorus and Mentha longifolia 
have PDE-4 inhibitory activity,  
(ii) Determine and compare the levels of the total phenolic compounds, the total 
flavonoids, especially luteolin and hesperetin, in the 3 plant species, and 
(iii) Determine if there was a correlation between the PDE inhibitory activity and 
the levels of flavonoids or phenolic compounds in the plants.  
 
3.2 Hypothesis 
 
It was hypothesized that the plants with higher levels of total flavonoid and/or aglycone 
luteolin and/or hesperetin had higher PDE - 4 inhibitory activity.  
 
3.3 Study approach 
  
To realize the above objectives suitable preparations of the three plants (viz. freeze-dried 
aqueous extracts) were to be prepared, a suitable method to determine PDE inhibition 
selected and sensitive assay procedures used to determine the levels of total flavonoid 
and the aglycone forms of luteolin and/or hesperetin in the plant materials.  
 
3.3.1 Why Artemisia afra, Leonotis leonorus and Mentha longifolia and their 
aqueous extracts? 
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Artemisia afra, Leonotis leonorus and Mentha longifolia are, in South African traditional 
medicine, among the most popular medicinal plants advocated for the treatment of 
respiratory diseases such as asthma (Thring and Weitz, 2006). These plant species have 
been shown to possess respiratory smooth muscle relaxant properties, although little is 
known about the mechanisms for this effect. Nevertheless, they do contain flavonoids, 
and possibly other chemicals, which in turn have been linked to smooth muscle relaxant 
effects (Ko et al., 2004).  
 
In traditional practice, these plants are mainly used as an infusion or decoction of the 
loose leaves in hot water (Dube, 2006; Ma, 2006). Therefore, as per traditional method of 
preparation, aqueous extracts of Artemisia afra, Leonotis leonorus and Mentha longifolia 
leaves would be the most appropriate form of the plant to use in an investigation of the 
mechanism that may underpin the bronchial smooth muscle relaxation properties of these 
plant medicines and the plant chemical constituents possibly involved. The aqueous 
extracts are relatively easy to prepare, convenient to store and relatively stable (and thus 
consistent in chemical composition) if properly stored. 
 
3.3.2 Why the PDE 4 inhibitory activity and the BIOMOL GREENTM method?  
 
PDE 4 isozyme plays a particular important role in inflammatory and immunomodulatory 
cells. Inhibition of PDE 4 in all these cells produces a marked reduction of inflammatory 
immunomodulatory response. Moreover in vivo PDE 4 inhibitors reduce the tone of 
bronchial smooth muscle and produce bronchodilation. Over the last decade considerable 
attention has focused on cyclic nucleotide phosphodiesterase isozymes 4 as a molecular 
target for drugs for the treatment of pulmonary diseases. In addition, some studies have 
shown that luteolin and apigenin, which are found in Artemisia afra, Leonotis leonorus 
and Mentha longifolia, inhibit the activity of PDE 4 (Ko et al., 2005). Taken together 
these data suggest that PDE 4 inhibition may be one of the mechanisms through which 
these plants produce the relaxation of the tracheal smooth muscle in the treatment of 
asthma.  
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Several methods may be used to determine PDE inhibitory activity. For this study, the 
BIOMOL GREENTM Phosphodiesterase Assay Quantizyme was selected because it 
offered many advantages such as compatibility with the plant material, high assay 
sensitivity, convenience, rapidity, non-radioactivity and suitability for microplate or 
cuvette assay. In addition, this phosphate detection method has a moderate cost and uses 
a one-reagent step for phosphate detection. The other methods have disadvantages such 
as high cost and high potential for compound interference. 
 
3.3.3 Why Luteolin or hesperetin?  
 
Some studies have shown that the flavonoid luteolin possesses a tracheal muscle relaxant 
effect that may be mediated via inhibition of cAMP and/or cGMP phosphodiesterase 
(PDE), and that luteolin and hesperetin inhibit the activity of PDE 1 to 5 (Ko et al, 2004). 
In addition, luteolin has been found abundantly in Artemisia afra and Leonotis leonorus 
and hesperetin in Mentha longifolia. These two flavonoids may thus contribute to any 
PDE inhibition these plants may produce. At the same time, these two aglycones could 
also serve as marker compounds for the flavonoid group as a whole. Furthermore, their 
levels in the aqueous extracts of the plants could be easily quantified by HPLC assay 
because it is a sensitive, rapid and economical technique, while the total flavonoid levels 
and the total phenolic content in the plants could be measured by rapid, cheap, sensitive 
colorimetric methods viz the aluminium chloride method and the Folin-Ciocalteu 
method, respectively (Meda et al., 2004).  
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CHAPTER 4 
 
METHODS AND MATERIALS 
 
In this chapter, the materials, reagents, equipment, methods and procedures used to, (1) 
prepare the various plant materials, (2) determine the PDE 4 inhibitory activity of the 
plants and (3) quantify the levels of luteolin and hesperetin, as well as the total flavonoids 
and the total phenolic compounds in the plant extracts, are presented. 
 
4.1.  Chemicals, reagents, materials and equipment 
4.1.1  Chemicals  
 
Acetonitrile and methanol were purchased from Burdick & Jackson (USA); ethyl acetate, 
dimethylsulfoxide (DMSO), ethanol, malachite green, aluminium chloride from Merck 
(Darmstardt, Germany); formic acid, ammonium molybdate, potassium acetate, sodium 
carbonate from BDH Chemicals Ltd (England); hydrochloric acid from Kimix (USA), 
Amberlite MB-1 (desalting resin), trizma base from Sigma Aldrich (St Louis, USA); 
potassium dihydrogen phosphate from Riede de Haen (Germany), while the distilled 
water used was purified using the Analyst HP water purifier. 
 
4.1.2  Reagents  
 
Phosphodiesterase 4 (PDE 4), cyclic adenosine monophosphate (cAMP), isobutyl methyl 
xanthine (IBMX) were purchased from Sigma-Aldrich (St Louis, USA) and 5’-
nucleotidase from Biomol TM (USA). All these reagents were used as per the Biomol 
GreenTM PDE inhibitory assay and were stored in a freezer at – 20 or – 70 °C. Luteolin, 
hesperetin, morin, rutin and quercetin and the Folin Ciocalteu reagent were purchased 
from Sigma –Aldrich (Darmstardt, Germany).  
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4.1.3 Materials 
 
 A. afra and L. leonorus leaves were collected from Cogmanskloof in Montague in the 
Western Cape Province of South Africa, and M. longifolia leaves from Kirstenbosch   
National Botanical Garden in Cape Town, South Africa. In addition, sterile 96-well 
polystyrene microplates with lid (B&M Scientific, Cape Town, South Africa), 0.45µm 
Millipore syringe filters (Separations, (PTY) Ltd, Cape Town, South Africa) were used. 
 
4.1.4  Equipment 
 
The equipment used included an oven Memmert 854 schwabach (West Germany); a 
balance 1 Model GA 110(Wirsam scientific & Precision Equipment (PTY) Ltd., West 
Germany); a balance 2 Mettler Pe 6000 (Mettler instrumente Ag Ch-8606 Greifensee-
Zurich, Switzerland); a hot plate Type Rct 13 (Kika-Werke Gmbh & Co. KgD-79219 
Staufen, Germany); a spectrophotometer Beckman DU 640 ( USA); a microplate reader 
Labsystems Multiskan®, Bichromatic; an ice-bucket; a -70°C freezer MaldonR, model 
CFC U 85360 (England), a -26 °C freezer; a refrigerator; a freeze-dryer Model Virtis 
Freeze Mobile 72sl ( the Virtis company Gardner, New York, USA); a filtration system 
Supelco; a vacuum pump Medi-pump Model 1132-2 (Thomas industries, Inc, USA);a 
dessicator; a water bath Cph 110 ( Labdesign Engineering Pty Ltd.); 9.0 cm filter papers 
Watman® (England); a centrifuge Labofuge 200 (Germany); a vortex mixer G-560E 
(Scientific industries, Inc. Bohemia, NY. 11716 USA); a pH meter Basic20 (Crison 
Instruments, S.A.); micropipettes Gilson (Medical Electronics (France) S.A.); an 
AgilentTM 1200 HPLC system, an HPLC system consisting of an auto sampler Beckman 
Gold Module 507, a programmable binary gradient pump Beckman Gold Module 126 
series, diode array detector Beckman Gold Module 168 series and PC system monitored 
and controlled via a Beckman System Gold 32-KaratTM HPLC software system Beckman 
(Fullerton CA,USA); an hydro-reverse phase column Phenomenex (USA) having 4µm 
particle size and a column length of 250 x 4.60mm.  
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4.2  Methods and procedures 
4.2.1  Preparation of freeze - dried aqueous extracts of A. afra, L. leonorus and M. 
longifolia                     
          
The fresh leaves of A. afra were collected in Montagu in the Western Cape Province of 
South Africa in February 2005. A voucher specimen (voucher No: 6735) was deposited 
in the herbarium, Botany Department, University of the Western Cape. The leaves were 
washed with water and dried in the oven at 60°C for 3 days under strict hygienic 
conditions. 
 
The fresh leaves of L. leonorus were collected from Cogmanskloof in Montagu in the 
Western Cape Province of South Africa on 7th March 2005. A voucher specimen 
(voucher No: 6736) was deposited in the herbarium, Botany Department, University of 
the Western Cape. These leaves were also washed with water and dried in the oven at 
60°C for 3 days under strict hygienic conditions. 
 
Finally, the fresh leaves of Mentha longifolia were collected from Kirstenbosch Garden 
Western Cape Province of South Africa on 21st March 2004. A specimen of the collected 
plant (voucher No: 6635) was deposited in the herbarium, Botany Department, University 
of the Western Cape. These leaves were treated as for the L. leonorus and A. afra.  
 
For all three plants the dried plant material were packed in plastic bags which were then 
put in brown paper bags and stored at room temperature until they were extracted.  
 
The aqueous extracts of the dried plant materials were prepared using a procedure 
mimicking the methods used by the traditional healers who usually take 1l of boiling 
water to extract one teaspoon of dried Artemisia afra, Leonotis leonorus or Mentha 
longifolia leaf powder (i.e. about 2.5g). Thus, in this study, 100g dried Artemisia afra 
leaves were boiled in 3500ml of distilled water for 10 minutes, cooled, the solution 
filtered and the filtrate frozen at -26°C and finally vacuum freeze-dried over 3 days at – 
45 °C. Once it was dried, it was collected, placed in an amber bottle and kept in a 
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desiccator until use. The same procedure was used for the preparation of the freeze-dried 
L. leonorus and M. longifolia aqueous extracts. 
 
4.2.2  Determination of the PDE inhibitory activity of the plant extracts. 
 
The method used to evaluate the PDE-inhibitory activity of the plant extracts was the 
Biomol GreenTM Phosphodiesterase assay method (www.biomol.com). To use the 
Biomol GreenTM method to assess the PDE–inhibitory activity of the plants, aqueous 
solutions of the plant extracts first had to be desalinated before the PDE-activity could be 
measured and for this, a suitable protocol had to be developed.  
 
4.2.2.1  Desalination of plant extracts 
 
The Malachite Green reagent used in the Biomol GreenTM Phosphodiesterase assay is a 
highly sensitive phosphate detection solution that changes in colour from yellow to green 
in the presence of free phosphate (e.g. any phosphate present on labware, in the reagent 
solutions, etc.). When 100 µl of Malachite Green solution was added to 50 µl of 0.5 
mg/ml aqueous solutions of each plant extract the solution turned green indicating the 
presence of phosphate in these solutions. To remove the excess phosphate, aqueous 
solutions of the plant extracts were first desalted using Amberlite MB-1, an ion-
exchanger resin. 
 
For the desalination process, 10 g of the resin (Amberlite MB-1), placed in a 500ml 
beaker, was rehydrated by adding 250ml of phosphate free deionized water, and stirred 
for 4 hours. Thereafter, the water was carefully decanted and the rehydrated resin put into 
a 5ml plastic syringe to obtain a 5ml settled-bed volume column of resin. The water was 
allowed to drain by gravity, the column equilibrated by adding 4ml of 10 mM Tris-HCl 
buffer at pH 7, 4 and this was also allowed to drain by gravity. 
 
To desalinate, 2 ml samples of the unhydrolyzed plant solutions or a 10 μg/ml phosphate 
solution (as control) was added to the top of the column, allowed to drain by gravity and 
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the effluent collected. To test for the effective quantitative removal of phosphate from the 
extract or phosphate solutions, 100μl of Malachite Green reagent was added to 50μl of 
extract, phosphate solution (both non-desalinated), a separate sample of deionized water 
(blank) or samples of the extract and phosphate solution effluents (i.e. that collected after 
passing through resin) in a 96-well microplate.  Twenty minutes later the absorbance of 
the contents of each well was measured at 620nm using a microplate reader. The 
effective removal of the phosphates by desalination was assessed by comparing the 
optical density (OD) of the pre- and the post-desalinated plant solutions with that of the 
phosphate-free deionized water. After this, the desalted extract solutions were 
immediately frozen and stored at - 26°C until tested for PDE inhibitory activity.  
 
4.2.2.2.  Protocol for the PDE inhibitory assay 
 
For the assay, several reagents needed to be prepared and the method validated by using 
different concentrations of a known PDE inhibitor, isobutyl methyl xanthine (IBMX), as 
a positive control. The procedure used to analyze the data obtained is also described 
below. 
 
4.2.2.2.1.  Solutions: 
 
Firstly, the following solutions were prepared:   
a) 10 mM Tris-HCl, pH 7.4 assay buffer 
b) 0.05 mU/ml PDE 4 in assay buffer 
c) 1 mM of 3’5’cyclic- adenosine monophosphate (c-AMP) in assay buffer   
d)         Malachite Green solution (Harder et al., 1994).  
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4.2.2.2.2.  Validation of the method and assay for cAMP-PDE 4 inhibitory 
activity  
 
The Biomol GreenTM assay method is based on the cleavage of cAMP or cGMP by a 
cyclic nucleotide phosphodiesterase (www.biomol.com). The 5’-nucleotide released in 
the reaction is further cleaved to the nucleoside and phosphate by the enzyme 5’- 
nucleotidase and the phosphate released quantified using BIOMOL GREENTM reagent. 
In the present study, cAMP was used as the substrate, and isobutyl methyl xanthine 
(IBMX), a well-known non-specific PDE inhibitor, as a positive control.  
 
To validate the assay the PDE- inhibitory activities of various concentrations (200, 100, 
50 and 25, 10 μM in assay buffer) of IBMX were first determined. An aqueous stock 
solution of 10mg/ml of each desalinated plant extract was diluted in deionized water to 
obtain 25, 50, 125, 250, 500, 1000 and 2000 μg/ml solutions of unhydrolyzed extracts, 
and 1ml of the 10mg/ml stock solution was hydrolyzed with 1ml of 2M HCl and 
neutralized with 1ml of 2M NaOH for the hydrolyzed extracts and then diluted to provide 
the above concentrations. Thereafter, the assay was carried out with seven different 
concentrations (25, 50, 125, 250, 500, 1000, 2000 μg/ml) of the unhydrolyzed and the 
hydrolyzed plant extracts. This was achieved by placing 10 µl of buffer into wells of a 
96-microtiter plate and then successively adding 40 µl of the substrate (1 mM cAMP), 10 
µl of IBMX or the unhydrolyzed or hydrolyzed plant extract sample, and 10 µl of 5-
nucleotidase to each well. The volume was then adjusted to 80μl with deionized water if 
necessary. Finally, 20 µl of PDE (20 mU) was added to start the reaction and the 
microtiter plate placed in an incubator at 30 ˚C for 90 minutes. To terminate the 
reactions, 100 µl of Malachite Green solution was added and the plate gently agitated to 
mix the contents (taking care to avoid the production of air bubbles in the wells). The 
colour was allowed to develop for 20 minutes before reading on the microplate reader 
taking care to assure that the samples spend approximately the same time in contact with 
the reagent. Finally, the optical density at 620nm was read for each well on a microtiter-
plate reader. 
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The net increase in optical density (OD) was calculated as the OD in the presence of 
enzymes and substrates (with and without test compound present) minus the OD obtained 
when the substrate and the compound tested were not present (background OD). The 
PDE inhibitory activity was assessed by calculating the percentage inhibition as follows: 
 
% Inhibition=   Net OD without inhibitor-net OD with inhibitor     x 100 
                                                           Net OD without inhibitor 
 
Thereafter the plant extract solution concentration versus % inhibition data was entered 
into the Graphpad Prism 4 Program, sigmoidal concentration-response curves of A. afra, 
L. leonorus and M. longifolia extracts plotted and the concentrations inducing 50% of the 
maximum inhibition (i.e. IC50) estimated.  The latter parameter was subsequently used to 
compare the PDE inhibitory effects of the three plant species. 
 
4.2.3. Determination of total flavonoid content in the plant material 
 
The total flavonoid content of the plants was determined using the aluminium chloride 
colorimetric method (Meda et al., 2005) and quercetin was used to establish the 
calibration curve. For the latter purpose, 10 mg of quercetin were dissolved in 10ml of 80 
% ethanol in water (v/v) and then diluted with 80 % ethanol to provide 25, 50, 100, 200 
and 250 μg/ml solutions. To 0.5 ml of each standard solution 1.5 ml of 95 % ethanol 
(v/v), 0.1 ml of 10% aluminium chloride, 0.1 ml of 1M potassium acetate and 2.8 ml of 
distilled water was added and the contents of the tubes incubated at room temperature for 
30 minutes, where after the absorbance of the reaction mixture was measured at 415 nm 
using a UV/VIS spectrophotometer. For the blank the amount of 10 % aluminium 
chloride was substituted by the same amount of distilled water in the blank. To establish 
the standard curve to be used in the quantification of the total flavonoids, the optical 
densities (OD) of quercetin were plotted against the corresponding concentrations.  
 
The total flavonoid content in the plants was obtained as follows: 2.5 mg of each plant 
were weighed and placed in a screw-capped Kimax tube, then dissolved in 0.5 ml of 
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distilled water. To hydrolyze the sample, 1 ml of 2 M hydrochloric acid were added to the 
solution and the mixture heated at 80°C for 40 minutes in a water bath. The solution was 
allowed to cool and then neutralized with 1ml of a 2M NaOH solution. To determine the 
total flavonoid content in the unhydrolyzed and hydrolyzed samples, the solutions were 
reacted with aluminium chloride as described above. The OD of the mixture was read at 
415nm and the quercetin standard curve used to determine the corresponding flavonoid 
concentrations in the plant extract (hydrolyzed and unhydrolyzed) samples. The total 
flavonoid levels in the desalinated plant extracts were obtained in a similar fashion.  
 
4.2.4.  Determination of the total phenolic content (TPC) in plant material 
 
The total phenolic content of the plants was determined using the Folin Ciocalteu method 
(Meda et al., 2005). Rutin was used as the standard to establish the calibration curve. For 
the latter purpose, 10mg of rutin was dissolved in 10ml of water (v/v), and then diluted to 
provide 50, 100, 150, 200, 250 and 500 μg/ml solutions. To 0.5 ml of each standard 
solution, 2.5 ml of 0.2N Folin-Ciocalteu reagent was added and left to stand for 5 min. 
Then 2 ml of 75g/ml solution of sodium carbonate (Na2CO3) was added and the mixture 
incubated at room temperature for 2 hours. The absorbance of the reaction mixture was 
read at 765nm using a UV/VIS spectrophotometer, against a blank composed of distilled 
water and all the reactants except rutin. The absorbance readings obtained were plotted 
against the corresponding concentrations of rutin to establish the calibration curve for 
TPC determination in the plants. 
 
To determine the TPC, a 1mg/ml solution of each plant was prepared in distilled water 
and 0.5 ml of this solution used to quantitate the TPC in each plant. To hydrolyze the 
plant extracts, 0.5 ml of the 1mg/ml solution were placed in a screw-capped Kimax tube, 
then hydrolyzed and neutralized as described in the determination of the TFC in section 
4.2.3. The unhydrolyzed and hydrolyzed extracts of each plant were treated as described 
above and the Optic density (OD) of the mixture was read at 765nm. The rutin standard 
curve was then used to determine the corresponding phenolic concentrations expressed in 
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rutin equivalent per mg of plant extract. The TPC in the desalinated plant extracts were 
similarly obtained.  
    
4.2.5.  HPLC assay of luteolin or apigenin in the plant extracts  
4.2.5.1. Validation of the HPLC assay 
 
Luteolin and hesperetin were selected as markers for the HPLC analysis of A. afra, L. 
leonorus and M. longifolia. 
 
The luteolin levels in A. afra and in L. leonorus as well as the hesperetin level in M. 
longifolia were determined by HPLC using a reversed phase method. The mobile phases 
consisted of 30 % acetonitrile, 70 % KH2PO4 buffer (pH 2) for luteolin and 45 % 
methanol, 55 % formic acid 0.1% for hesperetin. These eluents were pumped 
isocratically, at room temperature (20°C) through a C18 reverse phase column 
(Phenomenex, 4μm particle size and 250 x 4.60 mm), at a flow rate of 1ml per minute. 
Morin was used as an internal standard in the HPLC assay for A. afra, luteolin and 
hesperetin as external standards for the HPLC assay of L. leonorus and M. longifolia, 
respectively. 
 
Morin was chosen as an internal standard because it was not present in the above plant 
materials, absorbed strongly at the luteolin absorption wavelength (349nm), was 
extractable in ethyl acetate, had similar physiochemical characteristics to luteolin, and 
had a retention time that did not interfere with other peaks from A. afra. For all the plant 
runs the diode array detector, scanning between wavelengths 168 and 349 nm, were used 
to detect the flavonoids 
 
To validate the HPLC assay, stock solutions of luteolin, hesperetin and morin (1mg/ml) 
were prepared in dimethyl sulphoxide (DMSO), stored at -20 °C in glass container 
wrapped in aluminium foil to protect it from light using aluminium foil. Standard 
solutions were prepared each day by diluting the stock solutions to 1, 2, 4, 8 and 16μg/ml 
of luteolin in distilled water, 5, 10, 15, 20, 25 μg/ml of hesperetin in distilled water and 
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100μg/ml of morin in distilled water. These concentrations were used to prepare the 
standard curve. When using the internal standard method 10 μg of morin was added to 
each concentration of luteolin. For each standard, 50 μl was injected onto the column and 
the luteolin and hesperetin peaks were detected at 349 nm and 280 nm, respectively. The 
peak height ratios between luteolin and morin were plotted against the corresponding 
concentrations of the injected standard for the internal standard method and the peak 
height of luteolin or hesperetin were plotted against corresponding concentrations of the 
injected luteolin or hesperetin for the external standard method.  
 
To validate the assay, the linearity, lowest limit of detection (LOD), limit of 
quantification (LOQ), accuracy and precision were determined. The Graphpad Prism 4 
Program software was used to calculate the mean and percentage coefficient of variance 
& the linear regression coefficient.  
 
4.2.5.2.   Quantification of luteolin or hesperetin in the plant extracts  
 
The freeze-dried aqueous extracts of the plants, prepared as described in section 4.1.2.1, 
were assayed in two ways, viz. by hydrolyzed and unhydrolyzed methods. The latter 
provides the level of free flavonoid and the former the level of total flavonoid.  
 
To determine the free flavonoid level 10mg of Artemisia afra aqueous extract, 25mg of 
Leonotis leonorus or 100 mg of Mentha longifolia was placed in a screw-capped Kimax 
tube and dissolved in 1ml of distilled water. Except for Mentha longifolia aqueous 
solution that was directly injected (25 μl) onto the HPLC column, 100 μl of morin 
solution (100 μg/ml) was then added as internal standard to the A. afra samples, followed 
by 5 ml of ethyl acetate to both A. afra and L. leonorus samples and the mixture vortex-
mixed for 1 minute and centrifuged for 10 minutes at 3000 rpm. The top layer of ethyl 
acetate was removed to another clean tube using a disposable plastic pipette, evaporated 
to dryness under a gentle stream of nitrogen and the residue reconstituted in 1 ml of 
mobile phase and filtered before 50 μl thereof was injected onto the HPLC column.  
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On the other hand the total flavonoid (free plus conjugated) levels were obtained by first 
hydrolyzing the plant extracts. For that purpose, 10mg of Artemisia afra, 25 mg of 
Leonotis leonorus or 100 mg of Mentha longifolia were weighed and placed in screw-
capped Kimax tubes and dissolved in 1 ml of distilled water. One hundred microliter of 
morin solution (100 μg/ml) was added as internal standard to the A. afra samples. Then to 
hydrolyze the sample, 2 ml of 2 M hydrochloric acid were added to the solution and the 
mixture heated at 80°C for 40 minutes in a water bath. The solution was allowed to cool 
after the heating, 5 ml of ethyl acetate added and the mixture vortex-mixed for 1 minute 
and centrifuged for 10 minutes at 3000 rpm. The top layer of ethyl acetate was removed 
to another clean tube using a disposable plastic pipette, evaporated to dryness under a 
gentle stream of nitrogen and the residue reconstituted in 1 ml of mobile phase before 
injection onto the HPLC column.  
 
To identify the luteolin or hesperetin in the plants, the UV-spectra and the 
chromatographic retention times of the pure luteolin or pure hesperetin peaks were 
recorded after each run and compared to the UV-spectra and the retention times of 
luteolin or hesperetin peaks in the chromatograms of the plant samples.  
 
To determine the level of luteolin or hesperetin in the desalinated samples, the plant 
extract samples were first desalinated as described in section 4.2.2.1 and thereafter 
prepared for HPLC assay using the above procedure. 
 
4.2.6. Correlation between the flavonoid markers, total flavonoid and phenol 
concentrations and the PDE 4 inhibitory activity of the plants 
 
To determine the relationship between the level of the total flavonoids, the total phenolic, 
or the luteolin or hesperetin levels in the plant and the PDE- 4 inhibitory activity of the 
plants (IC50), the Pearson correlation coefficient for the regression of each of these 
parameters versus the PDE - 4 inhibitory activity was calculated using the Graphpad 
Prism 4 program (GraphPad Prism 4, 2003).   
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CHAPTER 5 
RESULTS AND DISCUSSION 
 
In this chapter, the results obtained during the preparation of freeze-dried aqueous 
extracts of A. afra, L leonorus and M. longifolia and the determination of their PDE 4 
inhibitory activity, total flavonoid, total phenolic, luteolin and hesperetin contents and, 
finally, the possible correlation between the total flavonoid and total phenolic compound 
concentrations versus the PDE 4 inhibitory activity of the plants, are reported and 
discussed.  
 
5.1.  Preparation of freeze-dried aqueous extracts (FDAE) 
 
The freeze-dried aqueous extracts of Artemisia afra, Leonotis leonorus and Mentha 
longifolia were prepared from the dried leaves as described in section 4.2.1 and the yields 
of freeze-dried aqueous extracts obtained were 21.5 %, 19.40 % and 15.4% for Artemisia 
afra, Leonotis leonorus and Mentha longifolia, respectively. These yields were very close 
to those obtained by previous investigators, viz 19.9 % by Komperlla (2005) and 21.96 % 
by Dube (2006) for A. afra, 18.42 % by Ma (2006) for L. leonorus and 12.42 % by Ma 
(2006) for M. longifolia. The appearance of the freeze-dried aqueous extracts of 
Artemisia afra, Leonotis leonorus and Mentha longifolia are shown in Figures 5.1, 5.2 
and 5.3. The A. afra extract was a light brown, brittle and hygroscopic powder with a 
characteristic and aromatic odour. The extract produced by L. leonorus was brown, brittle 
and hygroscopic and had a characteristic odour while that obtained from M. longifolia 
was yellow-brown, brittle and hygroscopic with a mint like aromatic odour.    
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          Figure 5.1: The freeze-dried aqueous extract of A. afra 
 
 
          Figure 5.2: The freeze-dried aqueous extract of L. leonorus 
 
 
           Figure 5.3: The freeze-dried aqueous extract of M. longifolia  
 
 
 
 
 47
5.2. PDE inhibitory activity of Artemisia afra, Leonotis leonorus and Mentha 
longifolia 
 
The determination of the PDE inhibitory activity of the plants required desalination of the 
plant extracts, adaptation and validation of the PDE method and finally, use of this 
method to determine PDE 4 inhibitory activity. 
 
5.2.1. Desalination of plant extracts. 
 
For the PDE-inhibitory assay the plant extracts were desalinated using the double bed 
resin Amberlite MB-1 as described in section 4.2.2.1. First, a standard curve of various 
concentrations of phosphate in deionized water vs absorbance at 620nm that was linear 
over a range of 1 to 5 µg/ml (r2: 0.982) and corresponding to the equation y = 0.1783x – 
0.0058 where y = absorbance (620nm) and x = phosphate concentration (µg/ml), was set 
up. The amount of phosphates in the plant material before and after the desalination 
process was consequently determined from this standard curve and the UV absorbance of 
the aqueous solutions of the plant extracts, the amount of phosphates in the plants before 
and after the desalination process and percent phosphates removed through the 
desalination process are reported in Tables 5.1 and 5.2. 
 
Table 5.1:    UV absorbance and concentration of phosphates in deionized water and   
plant freeze-dried aqueous extracts solutions (50µg/ml), before and after 
desalination treatment 
 
Samples 
Absorbance at 620nm 
(AUFS),  
average ± SD (n=3) 
Concentration of 
 phosphate (µg /ml)
 of  plant extracts 
 solution (50 µg/ml), 
 average ± SD (n=3)
Deionized water 0.067 ± 0.002 0.404 ± 0.012 
Non-desalinated A. afra extract 0.760 ± 0.002 4.293 ± 0.011 
Desalinated A. afra extract 0.069 ± 0.001 0.419 ± 0.003 
Non-desalinated L. leonorus extract 0.227 ± 0.001 1.303 ± 0.006 
Desalinated L. leonorus extract 0.068 ± 0.001 0.414 ± 0.003 
Non-desalinated M. longifolia extract 0.652 ± 0.002 3.687 ± 0.011 
Desalinated M. longifolia extract 0.067 ± 0.002 0.406 ± 0.010 
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Table 5.2: The percent phosphates removed through the desalination process  
                        from the plant extract solutions 
 
Plant samples % phosphate removed 
A. afra 86.16±1.50 
L. leonorus 93.85±1.54 
M. longifolia 99.50±0.87 
 
The non-desalinated A. afra, L. leonorus and M. longifolia extracts contained 4.293 ± 
0.011, 1.303 ± 0.006 and 3.687 ± 0.011µg/ml (n=3) of phosphate, respectively, of which 
more than 85% was removed in the desalination process.  The non-desalinated L leonorus 
contained significantly less (one-way analysis of variance (ANOVA), p < 0.0001) 
phosphate compared to the other two plants. The residual phosphate levels remaining 
after desalination were similar in the three plant solutions and comparable to the level in 
the distilled water (ANOVA, p value: 0.1575). Clearly the plant solutions contained 
significant amounts of phosphate which would have interfered with the PDE activity 
assay, but which was also appropriately removed by the desalination process illustrating 
the suitability of the Amberlite MB-1 used for the removal of the phosphate.  
 
 Many studies that have, however, used Amberlite MB-1 for plant material desalination, 
have also reported a loss in certain other constituents of the plants. For instance, Davies 
(1988) in a study conducted on the quantification of sugars in potato tuber extracts, 
reported a decrease in the sugar contents after Amberlite MB-1-treatment of the extracts 
to remove organic anions. In the present study, the desalination process did actually also 
lead to a decrease in flavonoids, as is shown later in table 5.7. Since flavonoids have been 
implicated in the phosphodiesterase inhibitory activity of plants, this loss of flavonoids 
from the A. afra, L. leonorus and M. longifolia extracts during the desalination step may 
have significantly influenced the plants biological activity. Fortunately, even though a 
great loss of flavonoids was registered after the Amberlite MB-1-treatment of the plant 
extracts, these extracts were still able to demonstrate a substantial PDE 4 inhibitory 
activity as reported in section 5.2.3.  
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Collectively, the above results indicate that the plant extracts contained significant 
amounts of phosphate, which would have interfered with the PDE activity assay and were 
appropriately removed through the desalination process using Amberlite MB-1. Although 
a great loss of flavonoids was registered after the desalination process, the plant extracts 
were able to substantially inhibit the PDE 4.  
 
5.2.2. Validation of the PDE method 
 
To validate the method, isobutyl methyl xanthine (IBMX), a non-specific cyclic 
nucleotide phosphodiesterase inhibitor, was used as a positive control. As negative 
control the assay buffer was used in-place of plant solutions or IBMX and caused no 
change in PDE activity. The PDE 4 inhibitory activity of 6 different concentrations (5, 
10, 25, 50, 100,200 µM) of IBMX was evaluated and the results obtained are shown in 
table 5.3 and figure 5.4, the latter being a log concentration-response curve of the data 
fitted using a non-linear regression program. From this curve the concentration inducing 
50 % of the maximum inhibition (i.e. IC50) was estimated. 
 
        Table 5. 3:   The percentage PDE 4 inhibition of IBMX 
  
IBMX (µM) % PDE 4 inhibition ±SD (n=3) 
5 3.67 ± 0.58 
10 9.31 ± 1.57 
25 28.42 ± 3.15 
50 39.04 ± 2.29 
100 61.37 ± 1.52 
200 64.33 ± 1.15 
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         Figure 5. 4: Log concentration vs PDE-inhibitory response curve  
                    of IBMX. Each point is the mean of 3 replications. 
 
Under the experimental conditions (i.e. enzyme levels etc.) used in this study (see section 
4.2.2.2.2), IBMX showed a maximal % inhibition of approximately 60% and a PDE 4 
IC50 of 35.98 ± 0.035µM or 7.91 ± 0.008 µg/ml. These values were close to the PDE 4 
IC50 of approximately 25µM reported for IBMX in the Biomol Phosphodiesterase Assay 
(www.biomol.com) product brochure. Given these results the assay was thus deemed 
validated and used in this study.  
 
5.2.3.  PDE 4 inhibitory activity 
 
The PDE 4 inhibitory activity obtained for the plants in this study are shown in tables 5.4, 
5.5 and 5.6 and figures 5.5 and 5.6.  
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Table 5.4:   The % PDE inhibition induced by different concentrations of A. afra, L. 
leonorus and  M. longifolia unhydrolyzed aqueous extracts  
 
 
Plant concentration 
(µg/ml) 
% PDE inhibition (mean ± S.D, n=3) 
A. afra L. leonorus M. longifolia 
25 9.1 ± 0.25 7.62 ± 2.61 18.15 ± 0.66 
50 14.74 ± 0.92 15.23 ± 0.50 24.46 ± 1.72 
125 35.60 ± 3.26 38.86 ± 5.05 41.36 ± 0 
250 60.99 ± 2.15 49.70 ± 4.39 49.59 ± 0.29 
500 73.7 ± 0.25 82.33 ± 0.47 75.83 ± 0.47 
1000 79.85 ± 2.36 89.56 ± 0.94 97.39 ± 2.46 
2000 84.39 ± 2.49 93.33 ± 1.03 100 ± 0 
 
Table 5.5:   The % PDE inhibition induced by different concentrations of A. afra,  
                    L. leonorus and  M. longifolia hydrolyzed aqueous extracts  
 
Plant concentration 
 (μg/ml) 
% PDE inhibition (mean ± S.D, n=3) 
A. afra L. leonorus M. longifolia 
25 30.09 ± 2.52 19.50 ± 3.05 23.97 ± 3.21 
50 51.75 ± 1.24 32.02 ± 0.00 30.84 ± 1.28 
125 54.22 ± 2.99 51.49 ± 3.86 45.10 ± 4.37 
250 72.70 ± 1.32 67.61 ± 2.73 53.98 ± 0.37 
500 92.00 ± 0.00 95.23 ± 0.59 93.50 ± 0.71 
1000 93.26 ± 0.91 97.50 ± 0.71 99.57 ± 0.33 
2000 96.11 ± 1.45 99.19 ± 1.15 100.0 ± 0.00 
 
 
 
 
 Table 5.6:  The PDE inhibition IC50 values of IBMX and the unhydrolyzed  
                    and the hydrolyzed plants  
 
Sample IC 50 (µg/ml)  Unhydrolyzed plant Hydrolyzed plant 
A. afra 161.70 ± 1.806 144.0 ± 0.356 
L. leonorus 212.12 ± 0.040 167.3 ± 0.037 
M. longifolia 337.10 ± 0.042 280.2 ± 0.033 
IBMX 7.91± 0.008 
 
 
All three plants demonstrated a dose-dependent PDE 4 inhibition with a maximal 
inhibition of 84.39 ± 2.49 % and 96.11 ± 1.45 %; 93.33 ± 1.03 % and 99.19 ± 1.15 %, 
and finally 100 ± 0 % and 100 ± 0 % for the unhydrolyzed and the hydrolyzed aqueous 
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extracts of A. afra, L. leonorus and M. longifolia, respectively. Interestingly, at 
concentrations above 500µg/ml all three plants showed higher maximal PDE inhibitory 
activity than the highest dose of IBMX (44.45 µg/ml) used. 
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      Figure 5.5: Log concentration - PDE-inhibitory response curve of 
                          unhydrolyzed plant extracts. Each point being the mean of 3 replications. 
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  Figure 5. 6:   Log concentration- PDE-inhibitory response curve of hydrolyzed plan 
extracts. Each point being the mean of 3 replications. 
 
         
The PDE-4 inhibition IC50 of each plant, estimated from the concentration-response 
curves were 161.7 ± 0.01µg/ml; 212.1 ± 0.04 µg/ml and 337.1 ± 0.04 µg/ml for the 
unhydrolyzed extracts of A. afra, L. leonorus and M. longifolia, respectively while that 
for the hydrolyzed extracts were 144 ± 0.358 µg/ml; 167.3 ± 0.037 µg/ml and 280.2 ± 
0.0329 µg/ml, respectively. These PDE 4 IC50 results showed, for both the unhydrolyzed 
and hydrolyzed extracts, that A. afra was more potent than L. leonorus, which in turn was 
more potent than M. longifolia. In addition, although their PDE 4 IC50s were not 
statistically different (p value = 0.6232), the hydrolyzed extracts were more active than 
the unhydrolyzed extracts for all 3 plants i.e. there was a 10.95%, 21.12% and 16.87% 
decrease in the IC50 values for the hydrolyzed vs the unhydrolyzed extracts of A. afra, L. 
leonorus and M. longifolia, respectively. It is possible that the hydrolysis of the flavonoid 
glycosides lead to increased free aglycone (and sugars) levels that resulted in a 
subsequent increase in the level of PDE 4 inhibitory activity of the plants.  Such an 
interpretation is supported by the findings of Francisco Orallo et al. (2004) who studied 
the cyclic nucleotide phosphodiesterase-inhibitory effects of hesperetin and hesperidin. 
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They reported that the aglycone hesperetin inhibited the PDE 4 isolated from bovine 
aorta while its glycoside form, the 7-rhamnoglucoside (hesperidin) was inactive, the 
possible reason being that the glycosylation of the C7 atom produces a spatial 
configuration that does not favour interaction with the PDE 4 (Orallo et al., 2004). Ko et 
al. (2004) in their study on the inhibitory effects and structure–activity relationships of 
flavonoids on phosphodiesterase isozymes from guinea pig also reported that the 
aglycone luteolin was, in terms of PDE inhibition, more potent than its glycoside form, 
luteolin-7-glucoside, and probably because the bulky glycosyl residues at the 7- position 
may hinder its binding to the isozyme. The same study also reported that the structure of 
flavonoids determined their PDE inhibition. In fact, Ko et al. (2004) showed that, among 
others, (1) the C-3′ hydroxyl group of flavones was very important for PDE inhibition, as 
illustrated by luteolin being more potent than apigenin, and that (2) flavonols and 
isoflavones were more potent than flavones as illustrated by apigenin being less potent 
than genistein with regard to PDE 4 inhibition. Such differences in potency among the 
flavonoids based on their structure could partly explain the degree of potency of each of 
the presently studied plants.  
 
Finally, despite being able to produce higher maximal PDE inhibitory activity, the PDE 4 
IC50 values of the plants were however significantly (Student’s t-test, p value = 0.0118) 
higher than that for IBMX  (7.91 ± 0.008 µg/ml) clearly suggesting a much lower 
selectivity of the plant extract as far as PDE-inhibitory action is concerned. Such lower 
selectivity may also be the result of the presence of many plant constituents, each with a 
differing IC50 value, which may collectively contribute to the overall PDE – inhibitory 
activity of the plant extracts.  
 
Collectively, the above results indicate that all three plants dose dependently inhibited 
PDE 4, had roughly the same potency but were significantly less potent than IBMX, the 
positive control. In addition, the hydrolyzed extracts of the plants were slightly (although 
not statistically significantly) more active than the unhydrolyzed extracts suggesting that 
the PDE 4 inhibitory activity may be linked to the presence of the aglycone forms of 
flavonoids in the plants.   
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5.3. Total flavonoid content (TFC) of in the plant materials 
 
In this study the total flavonoid content (TFC) of the plant materials was determined 
using the aluminium chloride method. Quercetin was used to establish the calibration 
curve (figure 5.7), which was linear from 5 to 250 µg/ml (r2 = 0.9938). The total 
flavonoid content of the plant materials, expressed as quercetin equivalent (QE), are 
shown in tables 5.7 and figures 5.8 and 5.9. In addition, the percent of flavonoids lost 
during the desalination process of plant extracts is given in table 5.8.   
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                    Figure 5.7: Standard curve of quercetin concentration versus absorbance  
at 415 nm used for the quantification of the total flavonoid  
contents in  A. afra, L leonorus and M. longifolia.  
          (r2 = 0.  9938; slope = 0.0028 ± 0.00005447;  
y-intercept = 0. 03468 ± 0.002929) 
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Table 5.7: The total flavonoid content expressed in µg of quercetin equivalents (QE) per 
mg of unhydrolyzed and acid-hydrolyzed plant material, before and after the 
desalination process  
 
Plant Desalination Hydrolysis TFC (µg of QE /mg ± SD, n=3)  T test, p value 
A. afra 
No No 84.70 ± 3.88 
0.4387; NS No Yes 88.82 ± 3.56 
Yes No 20.61 ± 0.29 
0.2165; NS Yes Yes 28.40 ± 5.36 
L. leonorus 
No No 40.89 ± 0.02 
0.0124; S No Yes 92.60 ± 9.94 
Yes No 16.28 ± 0.36 
0.0058; S Yes Yes 70.76 ± 7.10 
M. longifolia 
No No 30.40 ± 1.08 
 0.0007; S No Yes 94.12 ± 3.94 
Yes No 16.84 ± 1.20 
0.0121;  S Yes Yes 50.80± 7.22 
Where S = p < 0.05 = statistically significant and NS = p > 0.05 = not statistically 
significant 
 
 
Table 5.8:  Percentage of the total flavonoid content (TFC) lost from the plant materials 
during the Amberlite MB-1desalination treatment 
 
Plant  % of TFC removed by desalination 
Unhydrolyzed A.  afra 75.67 
Hydrolyzed A. afra  68.03 
Unhydrolyzed L. leonorus 60.18 
Hydrolyzed L. leonorus  23.58 
Unhydrolyzed M. longifolia 44.61 
Hydrolyzed M. longifolia 46.79 
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Figure 5.8: The total flavonoid content (µg/mg) of the non-desalinated 
unhydrolyzed   extracts    of A. afra (AA unh), L. leonorus (LL 
unh) and M. longifolia (ML unh) and the desalinated unhydrolyzed 
plants (D unh AA, D unh LL, D unh ML). The p-values are for t-
test of TFC in unhydrolyzed plant levels vs that in desalinated 
                                    unhydrolyzed plant. 
 
 
Before the desalination treatment, the A. afra unhydrolyzed extracts clearly contained the 
highest levels of total flavonoids (84.70±3.88µg/mg), followed by L. leonorus (40.89 ± 
0.02µg/mg) and finally M. longifolia (30.4±1.08 µg/mg) (table 5.7 & figure 5.8). After 
desalination these levels were significantly (T test, p A afra = 0.0008, p L leonorus = 0.0002, p 
M longifolia = 0.0004) decreased, in all three extracts, (table 5.7 and figure 5.8) and, now, the 
TFC of the unhydrolyzed extracts of A afra was higher than those in the other plants 
which then were quite similar   16.28 ± 0.36µg/mg and 16.84 ± 1.20µg/mg (figure 5.8). 
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Figure 5.9:   The total flavonoid content (µg/mg) of the non-desalinated hydrolyzed 
extracts of A. afra    (AA hyd), L. leonorus (LL hyd) and M. longifolia (ML 
hyd) and the desalinated hydrolyzed plants (D hyd AA, D hyd LL, D hyd 
ML). The p-values are for t-test of TFC in hydrolyzed plant levels vs that in 
desalinated hydrolyzed plant. 
 
When the plant extracts were subjected to acid hydrolysis the levels of TFC in all 3 
extracts were relatively similar (ANOVA, p value = 0.624) and now the TFC for L. 
leonorus & M. longifolia were significantly increased compared to the levels in the 
unhydrolyzed samples (Student’s t-test, pL leonorus = 0.00124 and pM longifolia = 0.0007). 
Further, the desalination treatment did not affect the L. leonorus acid-hydrolyzed extract 
much, only 23.58 % of the initial flavonoid content was removed, while significantly 
more i.e. 68.03 % and 46.79 % of TFCs was removed from the hydrolyzed A. afra and M. 
longifolia extracts, respectively.  
 
The different plants and when they are subjected to hydrolysis and /or desalination with 
Amberlite thus produced several samples with different TFC levels. A. afra, L. leonorus 
and M. longifolia have all been reported to contain several flavonoids and because they 
are naturally different, their inherent flavonoid contents are different from each other. 
The increase in the total flavonoid content noticed after acid-hydrolysis can thus possibly 
be explained by the fact that the flavonoid glycosides present in the plant extracts broke 
down and produced aglycones that were able to complex with aluminium chloride 
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through binding at the ortho-dihydroxy-, hydroxy-oxo-, and ortho-hydroxy-oxo- groups 
(Smirnova et al., 1998). In the case of A. afra the increase was not significant probably 
due to the fact that the plant contained more aglycones than glycoside flavonoids, 
possibly because the extract absorbed some moisture during storage and was subject to 
hydrolysis.  
 
The decreased in the level of flavonoids following the desalination of the plant extracts 
using Amberlite MB-1 was probably due to the fact that Amberlite, being a double bed 
resin, retained both anions and cations. Moreover, since Amberlite has been used in many 
studies to extract flavonoids for their quantification (D’Arcy, 2005), it was expected in 
this study that the desalination process might also decrease the levels of flavonoids in the 
plant extract solutions. 
 
Many investigators have used the aluminium chloride method used in this study to 
determine the total flavonoids content of plants and foods. For instance, Meda et al. 
(2004) used this method to determine the TFC in Burkina Fasau honey and reported that 
this method is only specific for flavones and flavonols and tended to underestimate the 
real total flavonoid content. This underestimation of the TFC may have some implication 
on the correlation between total flavonoid concentrations and the PDE 4inhibitory 
activity of the plants. 
 
Flavonoids play a crucial role in the phosphodiesterase inhibitory activity of many plants 
(Ko et al., 2004). And, as reported in section 5.2.3, the PDE 4 inhibitory activity of the 
plants investigated in the present study was dose-dependent (figures 5.5 and 5.6) 
suggesting that this activity may be related to the level of constituents such as flavonoids 
in the plants.  Therefore, differences in the inherent levels of flavonoids in the plants or 
changes in the level of flavonoids as caused by the desalination or hydrolysis processes 
could thus be expected to possibly affect the plants activities.  
 
Collectively, the above results showed that A. afra, L. leonorus and M. longifolia had 
different total flavonoid contents which were, for all three plants, decreased during the 
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desalination process. Hydrolysis significantly increased the TFC in the L. leonorus and 
M. longifolia extracts, but not in A. afra leading to relatively similar TFC in hydrolyzed 
extracts of all 3 plants. The difference in the TFC of A. afra, L. leonorus and M. 
longifolia could possibly affect the plants’ activities. 
 
5.4. Total phenolic compounds content (TPC) in the plant materials 
 
The total phenolic compounds content of the plant extracts was determined by the Folin-
Ciocalteu method using a rutin standard curve for quantification (Figure 5.10). The rutin 
standard curve was linear over a range of 50 to 500 µg/ml (r2: 0. 9959) and corresponded 
to the equation: y = 0.001521x + 0.1271, where y = OD 765nm and x = rutin 
concentration (µg/ml). The total phenolic contents of the plant extracts, expressed as rutin 
equivalents (RE), are shown in table 5.9 and figures 5.11 and 5.12. 
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          Figure 5.10: Standard curve of rutin for the quantification of the total 
                              phenolic contents of A. afra, L. leonorus and M. longifolia. 
                             (r2 = 0.  9959; slope = 0.001521 ± 0.0002692; y-intercept = 
0.1271 ± 0.007396) 
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Table 5.9: The total phenolic content, expressed in µg of rutin equivalents (RE) per mg 
of unhydrolyzed and hydrolyzed plant material, before and after the 
desalination process using Amberlite MB-1 
 
Plant desalination hydrolysis TPC (µg of RE/mg ± SD, n=3) T test, p value 
A.. afra 
No No 357.18 ± 8.99 0.0001;  S 
No Yes 489.36 ± 6.21 
Yes No 111.57 ± 4.56 0.0001;  S 
Yes Yes 121.64 ± 1.90 
L. leonorus 
No No 347.36 ± 3.04 0.0377;  S 
No Yes 371.72 ± 11.5 
Yes No 71.24 ± 3.040 0.0012;  S 
Yes Yes 96.66 ± 1.520 
M. longifolia 
No No 672.66 ± 0.00 0.0011;  S 
No Yes 833.41 ± 9.29 
Yes No 253.56 ± 7.44 0.0128;  S 
Yes Yes 277.24 ± 3.71 
Where S = p < 0.05 = statistically significant and NS = p > 0.05 = not statistically 
significant 
 
 
 
 
Table 5.10: Percentage of the total phenolic content (TPC) lost from the plant materials 
after the desalination treatment using Amberlite MB-1 
 
Plant  % of  TPC removed by the desalination process 
Unhydrolyzed A. afra 68.76 
Hydrolyzed A. afra  75.14 
Unhydrolyzed L. leonorus 79.49 
Hydrolyzed L. leonorus  74.17 
Unhydrolyzed M. longifolia 62.30 
Hydrolyzed M. longifolia 66.73 
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Figure 5.11: The total phenolic content (µg/mg) of the non-desalinated unhydrolyzed 
extracts of A. afra (AA unh), L. leonorus (LL unh) and M. longifolia (ML 
unh) and the desalinated unhydrolyzed plants (D unh AA, D unh LL, D 
unh ML). The p-values are for t-test of TPC in unhydrolyzed plant levels 
vs that in desalinated unhydrolyzed plant 
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Figure 5.12: The total phenolic content (µg/mg) of the non-desalinated hydrolyzed 
extracts of A. afra (AA hyd), L. leonorus (LL hyd) and M. longifolia (ML 
hyd) and the desalinated hydrolyzed plants (D hyd AA, D hyd LL, D hyd 
ML).  The p-values are for t-test of TPC in hydrolyzed plant levels vs that 
in desalinated hydrolyzed plant 
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Before the desalination treatment M. longifolia had the highest total phenolic compounds 
content (table 5.9 and figure 5.11) with the levels in A. afra and L. leonorus lower and 
quite similar (T test, p value = 0.1476). The desalination process removed more than 60 
% of the phenolic compounds in all three plants (table 5.10) and the 3 desalinated extracts 
differed from each other in TPC levels (T test, p < 0.0001), the level being highest in the 
M. longifolia extract. 
 
On the other hand, the acid-hydrolysis significantly increased the levels of TPC (p<0.05) 
in al three plant extracts (table 5.9 and figure 5.12).  The highest total phenolic content 
was registered in M. longifolia (833.41± 9.29 µg/mg) followed by A. afra (489.36 ± 
6.21µg/mg) and finally L. leonorus (371.72 ± 11.47µg/mg). However, more than 65 % of 
the TPC were removed from these hydrolyzed plant extracts during the desalination 
process (table 5.10).  All three plants are reported in the literature to contain phenolic 
compounds (Muganga, 2004; Van Wyk et al., 2000; Sharaf et al., 2005) and the increase 
in the TPC after the hydrolysis process thus suggests that the acid hydrolysis may have 
caused the break down of glycosidic forms of phenolic compounds into aglycones, thus 
increasing their levels. Moreover, since flavonoids are the most abundant phenolic 
compounds in the plants, the loss of phenolic compounds from the plants during the 
desalination process probably reflected mainly flavonoid loss, which in turn could have 
affected the phosphodiesterase inhibitory activity of the different plant species. 
 
Collectively, the above results indicate that A. afra, L. leonorus and M. longifolia extracts 
contained different levels of total phenolic compounds which however were not 
significant between A. afra and L. leonorus. These levels were increased by the 
hydrolysis process and decreased by the desalination process for all plant species. Finally, 
the difference in the TPC could affect the PDE 4 inhibitory activity of the plant species.  
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5.5. Quantification of luteolin or hesperetin in the plant extracts  
5.5.1. Validation of the HPLC assay 
 
The levels of luteolin or hesperetin in the plant materials were determined by a validated 
HPLC assay method. The results of the assay validation are summarized in table 5.11 and 
the linearity of the luteolin and hesperetin standard curves shown in figures 5.15 and 
5.16, and sample chromatograms of standard solutions of luteolin and hesperetin and the 
plant materials shown in figures 5.13, 5.14,15 and 5.17 to 5.23 
 
 
Figure 5.13: HPLC chromatogram showing the retention time of morin (10.600 min, 
peak M) and luteolin (13.917 min, peak L). Luteolin and morin were 
dissolved in deionized water and extracted with ethyl acetate. The 
chromatographic conditions are described in section 4.2.5. 
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Figure 5.14: HPLC chromatogram showing the retention time of luteolin (13.800 min). 
Luteolin was dissolved in deionized water and extracted with ethyl 
acetate. The chromatographic conditions are described in section 4.2.5. 
 
 
 
 
Figure 5.15: HPLC chromatogram showing the retention time of hesperetin 
(17.164 min). Hesperetin was dissolved in deionized water and the 
chromatographic conditions are described in section 4.2.4. 
 
 
As described in section 4.2.5, the luteolin levels in A. afra and L. leonorus extracts and 
the hesperetin levels in M. longifolia extract were determined by HPLC using a reversed 
phase method. The mobile phases consisted of 30 % acetonitrile and 70 % KH2PO4 
buffer (pH 2) for luteolin assay and 45 % methanol and 55% formic acid for hesperetin 
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assay. These eluents were pumped isocratically, at room temperature (20°C) through a 
C18 reverse phase column (Phenomenex, 4μm particle size and 250 x 4.60 mm), at a flow 
rate of 1ml per minute. Under the above conditions, the retention time of luteolin and 
morin, at 349 nm, varied between 13.133 minutes to 14.200 minutes (figure 5.13 and 
figure 5.14) and 9.17 to 10.922 minutes (figure 5.13), respectively. The retention time of 
hesperetin at 280 nm varied between 17.371 and 17.751min (figure 5.15). The peaks of 
luteolin, morin and hesperetin were symmetrical and the peak of morin was well 
separated from the luteolin peak when used as internal standard. While morin could have 
interfered with the other peaks in L. leonorus (figure 5.20) solutions or did not absorb at 
the wavelength used for hesperetin in the M. longifolia chromatogram, morin was well 
separated from and did not interfere with other peaks in A. afra (figure 5.19), indicating 
the suitability of morin as internal standard for the quantification of luteolin in A. afra. 
The retention times of luteolin and morin reported above, were comparable to those 
obtained by previous investigators (Dube, 2006 and Ma, 2006).                                                                      
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Figure 5.16:    Luteolin standard curve for the quantification of luteolin in  
 A. afra by HPLC assay. Linear regression equation: Peak 
height ratio = 0.5958 + 0.2144 x conc. (µg/ml); r2=0.9976 
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Figure 5.17:  Luteolin standard curve for the quantification of luteolin in  
       L. leonorus by HPLC assay. Linear regression equation:  
 Absorbance (mAU) = - 713.4 + 2205 x conc. (µg/ml);     
r2=0.9967 
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Figure 5.18:  Hesperetin standard curve for the quantification of 
hesperetin in M. longifolia by HPLC assay. Linear 
regression equation: Absorbance (mAU) = 0.8598 + 1.688 
x conc. (µg/ml); r2=0.9991 
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Table 5.11: The validation results of the HPLC assay for luteolin and hesperetin 
quantification in plant extracts. 
 
Validation parameter Luteolin assay  
in A. afra 
Luteolin assay  
in L. leonorus 
Hesperetin assay 
in  M. longifolia 
Limit of detection 
 ng/ml (LOD) 
20 ng 20 ng 25 ng 
Limit of quantification  
(LOQ) 
1µg/ml 1µg/ml 2 µg/ml 
Linearity  
(correlation coefficient) 0.9976 
0.9967 0.9991 
Intra-assay reproducibility  
(% RSD) 6.73 
1.06 0.85 
Inter-assay reproducibility 
 (% RSD) 
5.26 6.91 1.91 
 
The results of the assays validation are summarized in table 5.11. The assays were linear 
over a range of 1 to16 µg/ml and had a regression coefficient of 0.9976 and 0.9967 for 
luteolin quantification in A. afra and L. Leonotis, respectively. The assay for hesperetin 
quantification in M. longifolia was linear over a range of 2 to 25µg/ml and had a 
regression coefficient of 0.9991. The LOD was 20ng for both luteolin assays in A. afra 
and L. leonorus, and 25 ng for the hesperetin assay, while the LOQ was 1µg/ml for the 
luteolin assays and 2 µg/ml for the hesperetin assay. The % RSD calculated to determine 
the intra assay reproducibility were 6.73; 1.06 and 0.85 % for the luteolin assay in A. afra 
and L. leonorus and the hesperetin assay in M. longifolia, respectively. In the same order, 
the inter-reproducibility was 5.26; 6.91 and 1.91 %.      
 
In general the assays were specific and reproducible enough and linear over suitable 
concentration ranges to quantify luteolin in the A. afra and L. leonorus and hesperetin in 
the M. longifolia aqueous extracts. 
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5.5.2 Levels of luteolin or hesperetin in the plant extracts  
 
With a view to correlate the level of luteolin and hesperetin to the PDE 4 inhibitory 
activity of the plant extracts, luteolin and hesperetin were quantified in the hydrolyzed 
and the unhydrolyzed plant extracts before and after the desalination process using the 
validated assay methods.  
 
Using the retention time and the UV – spectra of the standard, luteolin, morin and 
hesperetin were identified in the plant materials as shown in figures (5.19, 5.20, 5.21, 
5.22 and 5.23). The results indicating the quantitated levels of luteolin & hesperetin are 
reported in table 5.12 and the percent of flavonoid lost during the desalination process 
reported in table 5.13. The fingerprint and the desalinated plant chromatograms are 
shown in appendices 1 to 11. 
 
 
 Figure 5.19: HPLC chromatogram of an unhydrolyzed extract of A. afra. 
Luteolin is represented by the peak L (retention time: 14.217 min) 
and morin by the peak M (retention time: 10.717 min). The 
chromatographic conditions are described in section 4.2.5. 
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Figure 5. 20: HPLC chromatogram of an unhydrolyzed extract of L leonorus. Luteolin 
is represented by the peak L (retention time: 13.733 min). The 
chromatographic conditions are described in section 4.2.5. 
 
 
 
 
 
 
Figure 5. 21: HPLC chromatogram of an unhydrolyzed extract of M.longifolia. 
Hesperetin is represented by the peak H (retention time: 17.110 min). The 
chromatographic conditions are described in section 4.2.5. 
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Figure 5. 22: HPLC chromatogram of a hydrolyzed extract of A. afra. Luteolin is 
represented by the peak L (retention time: 13.783 min) and morin by the 
peak M (retention time: 10.583 min). The chromatographic conditions are 
described in section 4.2.5. 
 
 
 
 
Figure 5. 23: HPLC chromatogram of a hydrolyzed extract of L leonorus. Luteolin is  
represented by the peak L (retention time: 13.983 min). The  
chromatographic conditions are described in section 4.2.5. 
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Table 5.12: Luteolin and hesperetin content (µg/mg of plant material) of the plant 
extracts 
 
Plant samples 
Luteolin concentration 
 (µg/mg of plant extract) 
Mean ± SD (n=6) 
Hesperetin concentration  
(µg/mg of plant extract) 
Mean ± SD (n=6) 
Unhydrolyzed plant hydrolyzed plant Unhydrolyzed  plant 
Hydrolyzed 
 plant 
A. afra 0.85 ± 0.042  0.92 ± 0.105  - - 
Desalinated A. afra 
0.52 ± 0.046 0.83 ± 0.046 - - 
L. leonorus 
0.427 ± 0.032 0.559 ± 0.075 - - 
Desalinated L. 
leonorus 0.126 ± 0.013 0.351 ± 0.040 - - 
M. Longifolia - -  0.147 ± 0.027 ND 
Desalinated M. 
longifolia - -  0.082 ± 0.018 ND 
Abbreviations: ND: not detected in the sample, -: not determined in the sample 
 
 
Table 5.13: Percent loss in luteolin and hesperetin contents of the plant during the  
desalination process 
 
Plant  
% of luteolin or hesperetin removed by  
the desalination process 
Unhydrolyzed A.  afra 38.82 
Hydrolyzed A. afra  9.78 
Unhydrolyzed L. leonorus 70.49 
Hydrolyzed L. leonorus  39.20 
Unhydrolyzed M. longifolia 44.22  
Hydrolyzed M. longifolia Not determined  
 
The unhydrolyzed and hydrolyzed aqueous extracts of A. afra and L. leonorus contained 
the following concentrations of luteolin: 0.85 ± 0.42 µg/mg, 0.92 ± 0.105 µg/mg and 
0.427 ± 0.032 µg/mg, 0.559 ± 0.075 µg/mg, respectively (table 5.12). After the acid-
hydrolysis, the levels of luteolin were slightly higher in the plant extracts (an increase of 
8.23 % and 30.91 % was registered for A. afra and L. leonorus, respectively) although not 
statistically significant for A. afra (T test, p = 0.2350), when compared to those in the 
unhydrolyzed extracts. This finding suggests that the unhydrolyzed extracts contained 
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luteolin glycosylated forms, which after hydrolysis, broke down and liberated the luteolin 
aglycone, as previous investigators have reported (e.g. Muganga, 2004).  In the case of A. 
afra, the increase was not significant probably due to the fact that the plant already 
contained more aglycones than glycoside flavonoids, possibly because the plant extract 
may have absorbed some moisture during the storage and this causing premature 
hydrolysis in the extract. 
The levels of luteolin in the unhydrolyzed and the hydrolyzed extracts of A. afra were 
also comparable to those obtained in earlier studies by Muganga (2004) and Mukinda 
(2005), respectively, while the free luteolin level estimated in the unhydrolyzed extracts 
and the total luteolin level obtained after the hydrolysis of L. leonorus extracts were 
comparable to those reported by Ma (2006). 
 
M. longifolia aqueous extract that was directly injected onto the column as described in 
section 4.2.5 contained 0.147µg/mg of hesperetin. However hesperetin was not detected 
in the hydrolyzed extracts probably because the hydrolysis process changed the nature of 
the compound. The levels of hesperetin found in the M. longifolia in the present studies 
were approximately 10 times higher than those obtained by Waithaka (2004). The 
difference in the time of harvest, the preparation of the plant extracts and the storage 
conditions may explain this variation in the plant composition (Croll and Cordes, 2006).  
 
Desalination caused a loss of luteolin in both plants. In the unhydrolyzed extracts, the 
levels of luteolin decreased by 38.82 % and 9.78 % for A. afra and L. leonorus, 
respectively, while it decreased by 70.49 % and 39.2 % for the hydrolyzed plant extracts. 
The level of hesperetin in M. longifolia extract was decreased by 44.22 % (table 5.13). 
One might expect that these changes might be reflected in the PDE-inhibitory activity of 
the plant extract, but because the PDE inhibitory assay was not conducted on the non-
desalinated plants, it is difficult, at this stage, to establish at which level the loss of total 
flavonoids or individual flavonoid marker (luteolin or hesperetin) during the desalination 
process could have affected the activity of each plant.  
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Finally, it must be remembered that the luteolin or hesperetin contents of these plants 
may have been higher if more appropriate solvents were used to prepare the plant extracts 
since water, which was used for the extraction of plant materials in this study, is not the 
best solvent for flavonoid extraction.  
 
Collectively, the above results show that the levels of luteolin were different in A. afra 
and L. leonorus and were higher in the A. afra extracts than in L. leonorus extracts. The 
levels of luteolin increased in both plants after hydrolysis, and decreased after the 
desalination process. Hesperetin could only be quantified in the unhydrolyzed aqueous 
extracts of M. longifolia and was not detected in the hydrolyzed extracts. In addition, the 
level of hesperetin decreased after the desalination process. 
 
5.6. Correlation between the flavonoid markers, total flavonoid and phenol 
concentrations and the PDE 4 inhibitory activity of the plants 
 
 
Since flavonoids are reported to inhibit PDE 4, and variable total flavonoid and phenol 
concentrations and PDE-4 inhibitory activities were obtained for the 3 plants studied it 
was also of interest to determine whether an actual correlation existed between the 
flavonoid markers levels, the TFC and TPC of the three plants and their PDE 4 inhibitory 
activity. Only the TFC, the TPC and the individual flavonoid levels versus PDE 4 IC50 
data for the desalinated plant extracts were assessed for a correlation because the PDE 4 
inhibitory activity was only determined on the desalinated extracts of the plant solutions 
and not on the non desalinated plant solutions which contained high level of phosphates 
which could have interfered with the Biomol PDE assay. The results of this analysis are 
summarized in table 5.14.      
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Table 5.14:   Correlation of the TFC, TPC, luteolin and hesperetin levels of the plants 
                      with the PDE 4 inhibitory activity (IC50) 
 
Unhydrolyzed 
plants 
PDE 4 IC50 
(µg/ml) ± SD 
TFC (µg of QE 
/mg) ± SD 
Pearson 
correlation 
coefficient (r)
TPC (µg of 
RE/mg) ± SD
Pearson 
correlation 
coefficient 
(r) 
Marker level 
(µg/mg) ± SD 
Pearson 
correlation 
coefficient 
(r) 
A afra 161.70 ± 1.80 20.61 ± 0.29 
- 0.618*  
111.57 ± 4.56 
0.88** 
0.52 ± 0.05 
-0.71** L leonorus 212.12 ± 0.04 16.28 ± 0.36 71.24 ± 3.04 0.126 ± 0.02 
M longifolia 337.10 ± 0.04 16.84 ± 1.20 253.56  ± 7.44 0.082± 0.02 
Hydrolyzed 
plants 
PDE 4 IC50 
(µg / ml) ± SD 
TFC (µg of QE 
 / mg) ± SD 
Pearson 
correlation 
coefficient (r)
TPC (µg of 
RE/mg)) ± SD
Pearson 
correlation 
coefficient 
(r) 
Marker level 
(µg/mg) ± SD 
Pearson 
correlation 
coefficient 
(r) 
A afra 144.0 ± 0.36 28.40 ± 5.36 
0.18* 
121.64 ± 1.90 
0.96** 
0.83 0.05 
-0.98** L leonorus 167.3 ± 0.04 70.76 ± 7.10 96.66 ± 1.52 0.351 0.04 
M.  longifolia 280.2 ± 0.03 50.80 ± 7.22 277.24 ± 3.71 - 
Hydrolyzed 
and 
unhydrolyzed 
extracts 
- - -0.18* - 0.82** - -0.72** 
 
Where *   = p value > 0.05: not significant 
** = p value <0.05: significant 
There was no correlation observed between the TFC and the PDE IC50 of the 
unhydrolyzed plants (r = - 0.61, p value = 0.0837), the hydrolyzed plants (r = 0.18, p 
value= 0.6367) and both unhydrolyzed and hydrolyzed extracts taken together (- 0.18, p 
value = 0.46). This lack of correlation between the TFC and the PDE IC50 of the plants 
aqueous extracts might have been because either the content of flavonoids was 
underestimated by the aluminium chloride method which only quantified the flavones 
and flavonols, or because the hydrolysis step degraded other compounds also involved in 
the PDE inhibitory activity. For instance, Meda et al. (2004) used the same method and 
found a low correlation between the TFC of some Burkina Fasau honey samples and 
their antioxidant activity. However, the lack of correlation between the TFC and the 
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PDE 4 IC50 of the plants could suggest that their PDE inhibitory activity was not only 
caused by flavonoids but other compounds may also be involved.   
 
A significant correlation was, however, found between the TPC and the PDE IC50 of the 
unhydrolyzed plants, the hydrolyzed plants and both hydrolyzed and unhydrolyzed 
extracts (r = 0.88, p value: 0.018, r = 0.96, p value < 0.0001, r = 0.82, p value < 0.0001, 
respectively) strongly suggesting that the phenolic compounds (e.g. flavonoids and 
phenolic acids) present in the plants may contribute to their PDE 4 inhibitory activity.  
 
 If one assumes that luteolin and hesperetin have approximately the same PDE 4 
inhibition potency, a correlation may then be established between luteolin or hesperetin 
levels and the PDE 4 IC50. A significant negative correlation was thus observed between 
luteolin or hesperetin levels and the PDE 4 IC50 of the unhydrolyzed extracts, the 
hydrolyzed extracts and the hydrolyzed and unhydrolyzed extracts combined (r = -0.706, 
p value = 0.034, r = - 0.988, p value = 0.0002, r = - 0.724, p value = 0.023, respectively). 
These results suggest that flavonoids could possibly contribute to the plant activity. In 
addition, the data also suggest that luteolin could be a good marker for the PDE 4 
inhibitory activity of A. afra and L. leonorus, but hesperetin may not for M. longifolia 
because it was not detected in the hydrolyzed extracts.   
 
In summary, there was no correlation between the TFC and the PDE 4 IC50 of the plant 
extracts, but a good correlation was established between the TPC and the flavonoid 
markers levels, luteolin and hesperetin levels, and the plants PDE IC50 suggesting that 
flavonoids and phenolic compounds may possibly contribute to the PDE inhibitory 
activity of A. afra, L. leonorus and M. longifolia.  
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CHAPTER 6 
CONCLUSIONS 
 
 
The specific objective of this study was to investigate whether Artemisia afra, Leonotis 
leonorus and Mentha longifolia have PDE-4 inhibitory activity, to determine and 
compare the levels of the total phenolic compounds, the total flavonoids and especially 
luteolin and hesperetin, in the 3 plant species, and finally, to determine if there was a 
correlation between the PDE inhibitory activity and the levels of flavonoids or phenolic 
compounds in the plants.  
 
It was hypothesized that the plants with higher levels of total flavonoid, total phenolic 
compounds or aglycone luteolin or hesperetin had higher PDE - 4 inhibitory activity.  
 
From the results obtained in this study the following primary conclusions can be drawn: 
 
 
1. Aqueous solutions of A. afra, L. leonorus and M. longifolia contain significant 
amounts of phosphate which can interfere with the Biomol Green TM PDE assay. 
Fortunately, however, the phosphate can also be appropriately removed by a 
desalination process using Amberlite MB-1, an ion exchanger resin, after which 
the Biomol Green TM PDE assay can indeed be effectively applied.  
 
 
2. Aqueous solutions of the freeze-dried aqueous extracts of A. afra, L. leonorus 
and M. longifolia have PDE 4 inhibitory activity. The latter was dose dependent, 
higher for the hydrolyzed than the unhydrolyzed extracts of the plants and quite 
likely linked to the presence of the aglycone forms of flavonoids. Based on the 
IC50 the order of PDE inhibition activity was A. afra > L. leonorus > M. longifolia 
but all less potent than isobutyl methyl xanthine (IBMX), a known PDE inhibitor. 
 
3. A. afra, L. leonorus and M. longifolia contain total flavonoids and total 
phenolic compounds contents which were highest in hydrolyzed extracts of the 
plants and were substantially decreased by desalinating using Amberlite MB-1 ion 
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exchanger resin. The TFC and the TPC for the desalinated extracts were in order 
A. afra > L. leonorus > M. longifolia and M. longifolia > A. afra> L. leonorus, 
respectively 
 
4. The freeze-dried aqueous extracts of A. afra contains higher levels of the 
marker luteolin than L. leonorus extracts, which increased in both plants after 
hydrolysis, and decreased after the desalination of the extracts with Amberlite 
MB-1 desalination process.  On the other hand, hesperetin was only quantified in 
the unhydrolyzed extracts of M. longifolia where its level was also decreased after 
the desalination process using the ion exchanger resin Amberlite MB-1.  
 
5. There was no apparent correlation between the TFC and the PDE 4 IC50 of the 
plant extracts, but the correlation was significant between the TPC and the 
flavonoid markers luteolin and hesperetin contents and the plants PDE 4 IC50 
suggesting that flavonoids and phenolic compounds may possibly contribute to 
the plants PDE 4 inhibitory activity. In addition luteolin may be a good marker for 
the PDE 4 inhibitory activity of A. afra and L. leonorus but not hesperetin for M. 
longifolia because it was not detectable in the hydrolyzed extracts of this plant 
species. 
 
In summary, A. afra, L. leonorus and M. longifolia possess PDE 4 inhibitory activity 
which may correlate with the TPC and the individual flavonoid markers, luteolin and 
hesperetin, levels of the plant species.  
 
Further studies are required to investigate whether the in vitro PDE 4 inhibitory activity 
of the plant species also occur in vivo. A good marker for M. longifolia and a good assay 
method for its quantification need to be found and the same study should also be 
conducted on different batches of plant materials to further clarify the possible role of 
flavonoids in the PDE inhibitory activity of these plants. However, it is clear that A. afra, 
L. leonorus and M. longifolia at least do have PDE 4 inhibitory activity which can 
contribute to their effectiveness in the treatment of asthma.  
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APPENDICES 
 
Appendix 1: HPLC chromatogram of a desalinated unhydrolyzed extract of L leonorus. 
Luteolin is represented by the peak L (retention time: 13.733 min). The 
chromatographic conditions are described in section 4.2.4. 
 
 
 
Appendix 2: HPLC chromatogram of a desalinated hydrolyzed extract of A. afra. 
Luteolin is represented by the peak L (retention time: 13.783 min) and   
morin by the peak M (retention time: 10.583 min). The chromatographic 
conditions are described in section 4.2.4. 
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Appendix 3: Chromatographic fingerprint of A. afra aqueous extract (λ: 349 nm, 
mobile phase acetonitrile (solvent A) / 0.1% formic acid (solvent B), 
gradient elution:  95% B (2min), 90% B (3min), 85%B (5min), 80% B 
(8min), 75% B (22min), 20 % B (5min)  
 
 
 
Appendix 4: Chromatographic fingerprint of the desalinated A. afra aqueous extract (λ: 
349 nm, mobile phase acetonitrile (solvent A) / 0.1% formic acid (solvent 
B), gradient elution:  95% B (2min), 90% B (3min), 85%B (5min), 80% B 
(8min), 75% B (22min), 20 % B (5min)  
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Appendix 5: HPLC chromatogram of a desalinated unhydrolyzed extract of L. 
leonorus. Luteolin is represented by the peak L (retention time: 13.783 
min). The chromatographic conditions are described in section 4.2.4. 
   
 
 
 
Appendix 6: HPLC chromatogram of a desalinated hydrolyzed extract of L. leonorus. 
Luteolin is represented by the peak L (retention time: 13.783 min). The 
chromatographic conditions are described in section 4.2.4. 
 
    
 
 
 
 
 
 
 90
 
Appendix 7: Chromatographic fingerprint of L. leonorus aqueous extract (λ: 349 nm, 
mobile phase acetonitrile (solvent A) / 0.1% formic acid (solvent B), 
gradient elution:  95% B (2min), 90% B (3min), 85%B (5min), 80% B 
(8min), 75% B (22min), 20 % B (5min)  
 
 
Appendix 8: Chromatographic fingerprint of the desalinated L. leonorus aqueous 
extract (λ: 349 nm, mobile phase acetonitrile (solvent A) / 0.1% formic 
acid (solvent B), gradient elution:  95% B (2min), 90% B (3min), 85%B 
(5min), 80% B (8min), 75% B (22min), 20 % B (5min)  
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Appendix 9: HPLC chromatogram of an unhydrolyzed extract of M. longifolia. 
Hesperetin is represented by the peak L (retention time: 13.783 min). The 
chromatographic conditions are described in section 4.2.4. 
  
 
Appendix 10: Chromatographic fingerprint of the aqueous extract of M. longifolia  (λ: 
349 nm, mobile phase acetonitrile (solvent A) / 0.1% formic acid (solvent 
B), gradient elution:  95% B (2min), 90% B (3min), 85%B (5min), 80% B 
(8min), 75% B (22min), 20 % B (5min)  
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Appendix 11: Chromatographic fingerprint of the desalinated aqueous extract of M. 
longifolia  (λ: 349 nm, mobile phase acetonitrile (solvent A)/ 0.1% formic 
acid (solvent B), gradient elution:  95% B (2min), 90% B (3min), 85%B 
(5min), 80% B (8min), 75% B (22min), 20 % B (5min) 
  
 
 
 
 
 
 
 
